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ROBERT PAUL AlTRING. Metabolism of Branched-Chain Amino Acids by Rat 
Skeletal Muscle: Regulation of Branched-Chain a-Keto Acid Dehydro-
genase. (Under the direction of Maria G. Buse.) 
Catabolism of the essential branched-chain amino acids (BCAA) by 
skeletal muscle of the rat was investigated. In diaphragm muscles 
incubated in vitro oxidation and transamination of leucine or valine 
were accelerated by diabetes or starvation overnight. In the presence 
of pyruvate, transamination of BCAA by diaphragms was increased; 
oxidation of BCAA by diaphragms from diabetic or starved rats was 
increased by pyruvate but was inhibited in diaphragms of normal, fed 
rats. The effects on transamination were verified by direct measure-
ments of the a-ketoisocaproate (KIe) product of leucine transamination. 
The effect of pyruvate on KIC oxidation by diaphragms was similar to 
the effect on leucine oxidation. Branched-chain a-keto acid dehydro-
genase (BCDH) catalyzes the conunitted step in BCAA catabolism, its 
activity is regulated by a reversible phosphorylation-dephosporylation 
cycle. A method to measure active (initial) and total (active + 
inactive) BCDH in a soluble preparation from muscle was developed. 
Initial BCDH activity in fed, postabsorptive rats was about 1 runol/ 
minI g muscle. Total acti vi ty was -35 nmol/min/ g muscle; thus -2% of 
BCDH was in the active state. Intravenous infusion of leucine rapidly 
increased BCDH activity in a dose-dependent fashion; activity subse-
quently declined in parallel with plasma leucine concentration. Valine 
had no effect on BCDH activity while isoleucine was effective only at 
high doses. BCDH activity increased after 25% or 50% but not 9% 
protein meals in rats fed an adequate protein diet. Feeding a 50% 
v 
protein diet chronically increased postabsorptive BCDH. Dose-dependent 
response of BCDH to leucine was blunted in rats fed 9% protein chroni-
cally. In insulinopenic diabetic rats plasma BCAA and muscle BCDH 
activity were increased. Insulin therapy or adrenalectomy of diabetic 
rats decreased plasma BCAA but BCDH activity remained elevated. 
Starvation increased BCDH activity significantly only after four days. 
BCDH activation in response to increased leucine was blunted in starved 
or diabetic rats. Conclusions: In normal fed rats, muscle BCDH 
activity increases in response to hyper1eucinemia from meal consumption 
or infusion. The response to hyperleucinemia is attenuated by diabe-
tes, starvation or consumption of a low protein diet. In diabetes 
increased muscle BCAA oxidation results from increased BCAA transami-
nation and increased BCDH activity. 
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The branched-chain amino acids (BCAA*; L-leucine, L-isoleucine and 
L-valine) are among the nine essential amino acids in man and the rat 
(156,158). As a group the BCAA account for a large proportion, about 
45% (157,158), of the total essential amino acid requirement in man. 
The substantial requirement for these amino acids is reflected in their 
abundance in proteins; they account for 35% of the essential and 14% of 
the total amino acids in skeletal muscle (159), the largest repository 
of metabolically active protein (44). Among the essential amino acids 
BCAA (and leucine in particular) are unique in several respects: 1) 
they are metabolized extensively by peripheral tissues other than the 
liver (77,126); 2) their circulating concentrations change markedly in 
states such as altered protein intake, starvation, hepatic failure and 
insulinopenic diabetes (172); and 3) there is evidence that leucine can 
regulate protein turnover other than in its role as a precursor for 
protein synthesis (29,127). 
Catabolism of the BCAA. 
The BCAA can be completely degraded by mammals and the catabolic 
pathways for the amino acids were established by a number of investi-
gators (reviewed in 125). The essential features of their catabolic 
pathways are shown in Figure 1. The initial two catabolic steps are 
* Abbreviations used in this chapter are: BCAA, branched-chain 
amino acids; BCKA, branched-chain a-keto acids; BCDH, branched-chain 
a-keto acid dehydrogenase; BCAT, branched-chain amino acid aminotrans-
ferase; Kle, a-ketoisocaproate. 




































































common to all three BCAA. The first step (I), involves transamination 
of the amino acid to its corresponding branched-chain a-keto acid 
(BCKA) by branched-chain amino acid aminotransferase (BeAT); i.e. 
leucine to a-ketoisocaproate (KIC), valine to a-ketoisovalerate, and 
isoleucine to a-keto-~-methylvalerate. The second (II), and committed 
step (thus rendering these amino acids essential), is irreversible 
oxidative decarboxylation of BCKA catalyzed by branched-chain a-keto 
acid dehydrogenase complex (BCDH). Further catabolism of the three 
branched-chain acyl-CoA products of BCDH action on the three BCKA 
diverges with respect to the enzymes and the specific catabolic 
products but in general the pathways are similar to J3-oxidation of 
fatty acids. 
There are several noteworthy features of these catabolic pathways. 
The ultimate products of leucine oxidation are acetyl-CoA and aceto-
acetyl-CoA, leucine catabolism therefore yields only ketogenic products 
and cannot contribute to gluconeogenesis. 3-Hydroxy-3-methylglutaryl-
CoA is an intermediate in leucine catabolism, thus its carbon skeleton 
can act as a direct precursor for cholesterol synthesis without 
oxidation to acetyl-CoA. Valine is ultimately catabolized to succinyl-
CoA, and therefore contributes only a gluconeogenic precursor. 
Catabolism of isoleucine yields propionyl-CoA and acetyl-CoA thereby 
providing precursors for both ketogenesis and gluconeogenesis. 
The existence of additional catabolic pathways for leucine deserve 
mention. A cytosolic enzyme which catalyzes 02-dependent oxidative 
decarboxylation of KIC has been identified in liver (161). This enzyme 
is an Fe-dependent dioxygenase (162.163) which catalyzes KIC oxidation 
5 
to ~-hydroxyisovalerate (Figure 2). The significance of this catabolic 
sequence in disposal of leucine is unknown but the product of this 
reaction appears to be an ideal precursor for sterol synthesis. 
requiring only activation to its CoA derivative to enter the sterol 
synthetic pathway; experiments using rat liver homogenates designed to 
demonstrate incorporation of a-ketoisocaproate carbons into cholesterol 
under conditions favoring utilization of this pathway were however 
unsuccessful (R.P. Aftring. M. Owens, and M.G. Buse, unpublished 
observations). 
Liver of mammals also synthesizes a cobalamin-requiring enzyme 
(leucine 2.3-aminomutase) which catalyzes the conversion of leucine to 
~-leucine (Figure 3; ref. 147). The resulting ~-leucine can be 
transaminated to ~-ketoisocaproate (an inherently unstable a-keto acid) 
which in a bacterial system was further catabolized to isobutyrate and 
acetate. In a group of patients with pernicious anemia serum leucine 
concentration was decreased while serum ~-leucine concentration was 
increased. This observation suggested the possibility that the ~-leu­
cine pathway operated in the direction of synthesis (148). Further-
more. ~-leucine was synthesized from valine, isobutyryl-CoA or bran-
ched-chain fatty acids in vitro in a rat liver system (148). The 
importance of this metabolic pathway is unknown, but it suggests that 
although leucine is essential in the diet (i.e. required for growth and 
positive N balance), manunals may have limited capacity to synthesize 
this amino acid. 











































Branched-chain amino acid aminotransferases. 
BGAT activity in tissues is comprised of at least three and perhaps 
more isoenzymes with somewhat different physical properties and 
substrate specificities (reviewed in 95,96). As a group they catalyze 
a pyridoxal-5 1 -phosphate dependent transamination reaction similar to a 
large number of others (e.g. aspartate aminotransferase, alanine 
aminotransferase). The reaction catalyzed is the transfer of the amino 
group from the branched-chain amino acid to an a-keto acid with 
production of the corresponding BCKA and amino acid (from the a-keto 
acid, see Figure 1). In general a-ketoglutarate is thought to be the 
preferred amino group acceptor in vivo for this group of enzymes but 
the branched-chain a-keto acids are also efficient amino group accep-
tors (13,174). 
The BeAT enzymes are present in all mammalian tissues examined. 
The highest activities were found in stomach, pancreas, lactating 
manunary gland, salivary gland and heart, intermediate activities in 
kidney, brain, and muscle and low activities in liver, spleen and lung 
(95,99). Three isoenzymes of BCAT have been described in the rat. 
Isoenzyme I was ubiquitous in tissues and actively transaminates all 
three BCAA; isoenzyme III, also active with all BCAA, was found only in 
brain, placenta and ovary (99). Isoenzyme II. present only in liver, 
was active with leucine and methionine and may exist as distinct 
cytosolic and mitochondrial forms (97). In human tissues isoenzyme III 
was found in many tissues but isoenzyme I was the predominant BCAT; 
isoenzyme II has not been identified in human tissues (72). 
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Branched-chain a-keto acid dehydrogenase complex. 
The BCDH complex is analogous to the pyruvate and a-ketoglutarate 
dehydrogenase complexes, requiring NAD+ and CoASH as cofactors for the 
oxidation of BCKA producing NADH and branched-chain acyl CoA (one 
carbon shorter than the BCKA) as end products (45,150,199, see Figure 
1). BCDH is a large multienzyme complex, located on the inner aspect 
of the inner mitochondrial membrane (119,180). Active BCDH consists of 
three enzymatic components (38,85,144,146): 1) a decarboxylase moiety 
(E1) composed of nonidentical a and ~ subunits with thiamine pyrophos-
phate as a prosthetic group; 2) a transacylase moiety (E2) with lipoic 
acid as a prosthetic group; and 3) a flavin-containing lipoamide 
dehydrogenase moiety (E3) which is probably identical to that found in 
the pyruvate and a-ketoglutarate dehydrogenase complexes (85,199). 
BCDH activity is subject to several types of regulation. The 
complex is subject to feedback regulation by NADH, its branched-chain 
acyl CoA products and perhaps catabolites of leucine distal to isova-
leryl-CoA (reviewed in 150). It was recently established that BCDH is 
regulated by a phosphorylation-dephosphorylation cycle similar to that 
described for pyruvate dehydrogenase (150,152). BCDH is inactivated by 
the action of a specific kinase which catalyzes ATP-dependent 
phosphorylation of serine residue(s) of the a-subunit of the decarboxy-
lase moiety (37,58,108,133). Purified BCDH kinase activity is inhi-
bited by BCKA (KIC » a-keto-a-methylvalerate > a-ketoisovalerate; ref. 
142). The non-physiological compound, a-chloroisocaproate, is a 
relatively specific and highly potent inhibitor of BCDH kinase, in vivo 
and in vitro (82). Purified inactive BCDH can be reactivated in vitro 
9 
by dephosphorylation of phosphoserine by the action of a non-specific 
phosphoprotein phosphatase, cytosolic phosphoprotein phosphatase II 
(69). There is evidence for a specific phosphatase for BCDH, purified 
from bovine kidney mitochondria, which may be responsible for reacti-
vation of the complex in vivo (40). BCDH phosphatase activity is 
unaffected by divalent cations and is inhibited by several di- and 
triphosphonucleosides in the absence of Mg2+ (40,152). Phosphatase 
activity is stimulated by protamine, poly(L-lysine), and histone H3 and 
inhibited by heparin, CoASH and several acyl-CoA products of BCAA 
catabolism (40,152). Recently, a protein inhibitor of BCDH phosphatase 
was purified from bovine kidney mitochondria. The protein inhibitor is 
distinct from protein phosphatase inhibitors -1 and -2 and appears to 
be specific for BCDH phosphatase (39,41). Mg2+ and spermine reverse 
the inhibitory effect of this protein on BCDH phosphatase (39,41). The 
system of a phosphoprotein phosphatase with a protein inhibitor is 
reminiscent of the cytosolic protein phosphatases I and II with their 
respective protein inhibitors I and II (reviewed in 36). Whether the 
BCDH phosphatase inhibitor is present in other tissues and if it has a 
role in the regulation of BCAA catabolism are unknown. 
Protein factors which can alter BCDH activity have been found in 
several tissues and plasma (137,141). A cytoplasmic protein factor 
which activates BCDH in liver mitochondria has been prepared from 
skeletal muscle and is also found in plasma t but not in smooth muscle, 
kidney or liver (141). This skeletal muscle factor also activates 
Q-ketoglutarate dehydrogenase but inhibi ts pyruvate dehydrogenase in 
rat liver mitochondria. A protein factor from kidney and liver 
10 
mitochondria activates phosphorylated BCDH, the effect does not involve 
dephosphorylation of the complex (57,198). This latter factor (termed 
BCDH activator protein) has been purified and was identified as free E1 
(decarboxylase) or an isoenzyme of E1, which presumably increases BCDH 
activity by replacing inactive (i .e. phosphorylated) E1 in the BCDH 
reaction (56,198). It is noteworthy that phosphorylated E1 has lower 
affinity for the complex than does the non-phosphorylated enzyme (38). 
The role of these protein effectors of BCDH activity in regulation of 
BCDH activity in vivo remains unknown. 
The discovery of interconvertible forms of BCDH presents a problem 
in the determination of BCDH activity in tissues, and casts doubt on 
the results and interpretation of early studies of BCDH activity. 
Studies of BCDH activity which consider the active and inactive forms 
find that BCDH is nonuniforrnly distributed between tissues (69,137, 
183). Liver, kidney and heart have large total quantities of BCDH 
(69,137,183). In livers of fed rats nearly all of the BCDH was in the 
active state, in kidney the complex was 50-70% active, and in heart the 
acti vi ty state ranged between 7% and 50% in studies from different 
laboratories (69,137,183). Total BCDH activity in skeletal muscle was 
lower than in other tissues examined (137,183), although direct 
comparisons of the measured activities are difficult due to differences 
in assay methods. Pats ton et a1. (137) estimated the BCDH was less 
than 20% active in detergent extracts of muscle mitochondria but the 
actual activity was below the limit of detection of their assay. In 
muscle homogenates Wagenmakers et ale (183) and Kasperek et a1. (100) 
found about 5-6% of BCDH was in the active state in fed rats. 
11 
Interorgan cooperativity in BCAA catabolism. 
A number of reports have established the importance of peripheral 
(non-splanchnic) tissues in BCAA catabolism. Studies of amino acid 
oxidation by eviscerated rat carcasses showed that of the essential 
amino acids only the BCAA were oxidized in the peripheral tissues and 
provided early evidence that BCAA are oxidized primarily by extra-
hepatic tissues, while other essential amino acids are oxidized by the 
liver (126). The importance of the peripheral tissues in BCAA oxida-
tion was confirmed in studies of hepatectomized dogs (122) and rats 
(86), in which the concentrations of most amino acids increased 
steadily while those of the BCAA remained unchanged or declined. A 
wide variety of extrahepatic tissues have the ability to oxidize BCAA, 
including skeletal muscle (25,132), kidney (46,47), brain (21,35), 
peripheral nerve (28), aorta (28), adipose tissue (59), and heart (25). 
Determinations of the clearance of amino acids in humans after a 
protein meal (49,54) or amino acid infusion (2,49,54,67) demonstrated 
that skeletal muscle is a prominent site for BCAA disposal (disposing 
of 65-70% of infused leucine, ref. 67). 
Although BCAT and BCDH are present in all tissues examined, their 
distributions in various tissues are markedly different (i.e. liver had 
low BeAT activity but high BCDH activity, muscle had high BCAT activity 
but low BCDH activity, and kidney had relatively high activities of 
BCAT and BCDH). The observation that perfused rat hindlimbs release 
substantial quantitities of BCKA when perfused with BeAA (90,91) led to 
the suggestion that there is interorgan cooperativity in the catabolism 
of BCAA (reviewed in 77). In view of the low activity of hepatic BCAT 
12 
it is thought that most BCAA entering the splanchnic circulation after 
a protein meal pass through the liver unaltered. Most BCAA from oral 
ingestion therefore enter the systemic circulation for distribution to 
peripheral tissues. In the periphery BCAA are taken up for protein 
synthesis and catabolism. In muscle some fraction of the BCAA which 
are transaminated to BCKA are oxidized by BCDH and the remaining BCKA 
enter the venous system and are distributed to other tissues for 
oxidation or reamination. Since liver has high BCDH activity it is 
thought to be an important site for the clearance of BCKA in the 
circulation and indeed hepatic-portal venous BCKA gradients in the rat 
show that liver clears virtually all BCKA supplied to it (112). 
The conceptual model of interorgan cooperation for BCAA metabolism 
is well supported in the rat, but its applicability to humans has been 
questioned (172). Studies of leucine metabolism by human muscle in 
vivo established that leucine is oxidized by muscle but consistently 
found considerably less export of the transamination product KIC (2,49) 
by human muscle than has been found for rat muscle (90,91). The 
difference in the systems was suggested to be due to different distri-
butions of BCDH in human and rat tissues. Khatra et a1. (102) reported 
that 60% of human total body BCDH was present in muscle while only 15% 
of the rat enzyme was present in muscle. However, these studies were 
done without knowledge of the phosphorylation-dephosphorylation cycle 
which regulates BCDH activity (as discussed above). Furthermore the 
BCDH activities obtained by these authors in rat tissues are much lower 
than recent estimates of these activities (94,151); 4-6 fold lower in 
liver and nearly 2 orders of magnitude lower in skeletal muscle. At 
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present, in the absence of measurements of BCDH activity in human 
tissues using more accurate methods it is difficult to assess the 
similarity of BCAA metabolism in man and rat, but there appears to be 
no compelling reason to dismiss data from the rat as inapplicable to 
humans. 
Alterations in BCAA metabolism by starvation, disease, and injury. 
Dramatic changes in plasma BCAA concentrations are observed under 
several conditions. In starvation, diabetes mellitus, and after injury 
the circulating concentrations of BCAA are elevated (4,18,51,139,154). 
In contrast, plasma BCAA are markedly depressed in hepatic failure, 
while the concentrations of aromatic amino acids are increased (62). 
These alterations of plasma BCAA concentrations presumably reflect 
changes in supply and/or removal. Despite increased plasma BCAA there 
is evidence for increased BCAA oxidation by skeletal muscle in starva-
tion, diabetes, and trauma (4,9,51). These results seem paradoxical in 
view of the fact that in short-term starvation, and probably in trauma 
as well, the source of increased BCAA is thought to be skeletal muscle 
(34,44). There is some dispute over whether the increased BCAA oxida-
tion observed in vitro in incubated muscles represents the in vivo 
response to starvation or diabetes. Studies of leucine oxidation in 
vivo in rats starved for three days however clearly demonstrated that 
whole body oxidation of leucine was increased (182). In vivo whole 
body oxidation of leucine was also increased in patients with type I 
diabetes after insulin withdrawal (154,179) and in starved obese 
patients (4). Despite increased BCAA oxidation, the leucine clearance 
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rate in diabetic patients (51) or in normal humans fasted for 3 (169) 
or 4 (51) days was decreased. 
Recent studies from Randle and coworkers (reviewed in 151) found 
that BCDH activity in kidney and liver from rats was decreased by 
alloxan-diabetes and 2 days starvation. BCDH activity in heart was 
unaffected by starvation but increased in diabetes. Earlier studies 
found no effect of starvation or diabetes on kidney or liver BCDH 
activity (69,184) but did not take into account changes in the BCDH 
activator protein which is present in liver and kidney. It was 
postulated that the decrease in whole body BCDH activity (considering 
only changes in kidney, liver and heart BCDH activity) in diabetes 
could explain the increased circulating BCAA in diabetes (151). This 
explanation may be inadequate though since no consideration was given 
to possible changes in BCDH activity in tissues such as skeletal muscle 
or brain or to the observations of increased whole body oxidation of 
BCAA in insulinopenic diabetes (154,179). Indeed, Brosnan and cowork-
ers have demonstrated increased BCAA clearance by the brain in diabetic 
rats (20), and determined that the activity state of BCDH in brain is 
increased by diabetes (21). Further study of protein degradation and 
the regulation of BCAA disposal, especially in skeletal muscle are 
required to fully elucidate the factors which contribute to increased 
BCAA in starvation, diabetes and trauma. 
The depressions in plasma BCAA observed in hepatic failure are most 
likely due to accelerated oxidation by peripheral tissues, as suggested 
by studies in hepatectomized animals (86,122). Skeletal muscle is a 
likely site for increased BCAA disposal. Indeed, increased clearance 
15 
of BCAA by the leg was observed in patients with decompensated liver 
cirrhosis (83). The activity of skeletal muscle BCDH in liver failure 
has not been determined and no factors identified which may cause 
increased BCAA clearance in hepatic failure. 
Effect of diet and meal consumption on BCAA metabolism. 
Plasma BCAA increased in parallel with the protein concentration of 
the diet in rats maintained on diets with protein content varying 
between 5% and 75% casein; other plasma amino acids remained constant 
or declined (10,145). These results suggest that BCAA oxidation does 
not increase proportionately with their dietary intake. This is in 
contrast to other essential amino acids whose plasma concentrations are 
essentially constant despite increased intake (145) . The adaptive 
advantage of this response to increased dietary intake of BCAA is 
unclear since increased amino acid concentrations in general can be 
toxic. This is certainly so for the BCAA as evidenced by Maple Syrup 
urine disease, a congenital disease with greatly decreased BCDH 
activity (42) which results in large increases in plasma BCAA and BCKA 
and is associated with mental retardation and diminished growth (43). 
Nevertheless whole body leucine oxidation increased in rats fed diets 
with increasing protein content (109), and in humans leucine oxidation 
was increased following a protein meal (87). Curiously, when animals 
are fed diets containing adequate protein but excesses of leucine, 
growth rates are diminished and circulating concentrations of valine 
and isoleucine are depressed (reviewed in 77). The site(s) of increa-
sed BCAA oxidation after a protein meal or during increased protein 
intake is not known, nor is the cause of depressed valine and isoleu-
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cine concentrations in the presence of elevated leucine. It is 
noteworthy however that BCDH activity in liver and kidney was greater 
in rats fed a normal diet (20% protein) than those fed a 9% protein 
diet (81,151). 
BCAA as regulators of protein turnover. 
In incubated diaphragm muscles from rats, leucine inhibited protein 
degradation and promoted protein synthesis (29,66,127). Similar 
effects on protein turnover were demonstrated in perfused rat hearts 
(128); the effect on protein synthesis was thought to involve initi-
ation of translation (128). In fasted rats in vivo t a mixture of BCAA 
given intraperitoneally after administration of insulin stimulated 
formation of more polysomes in the psoas muscle than were found after 
insulin alone (23) . In skeletal muscles incubated in vi tro J the 
effects of BeAA on protein synthesis were attributed to a specific, 
concentration-dependent effect of leucine (31 t 66,127). The inhibitory 
effect of BCAA on protein degradation however required metabolism of 
leucine to a-ketoisocaproate (127,176); proteolysis was inhibited by 
high concentrations of 3-methylvalerate in one study (127). It remains 
unclear if the positive effects of BCAA on protein turnover obtain in 
vivo. In isolated, perfused rat hindlimbs high concentrations of 
leucine increased protein synthesis in inunature rat preparations but 
not in preparations from adult rats (Ill). Bolus injection of 0.1 romol 
of leucine in vivo had no effect on skeletal muscle protein synthesis 
by fed t starved or protein-deprived rats (123), while infusion of a 
mixture of the three BCAA in starved rats stimulated protein synthesis 
in certain muscles (32). The mechanism(s) of the effects of leucine 
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(or its metabolites) on protein turnover remain undefined. However, a 
recent study suggests that glycoprotein synthesis may be involved in 
the stimulatory effect of leucine on protein synthesis since inhibitors 
of glycoprotein synthesis abolished the effect of a mixture of BCAA but 
not of insulin on protein synthesis in diaphragm muscles incubated in 
vitro (149). 
Therapeutic uses of BCAA. 
The reported anabolic effects of BCAA coupled with evidence for 
increased oxidation of BCAA in clinical states such as injury and 
sepsis (9,51,160) have generated considerable interest in the use of 
alimentation formulas supplemented wi th increased rations of BCAA in 
clinical nutrition. It is thought that increased supply of BCAA may be 
beneficial in improving nitrogen balance in selected patients, both by 
supplying additional substrate for oxidation and through their anabolic 
effects (reviewed in 189). The use of BCAA supplementation in injured 
or surgical patients is being encouraged despite the incomplete under-
standing of BCAA metabolism and its regulation and inconclusive and 
contradictory results in clinical studies. 
BCAA catabolism by skeletal muscle. 
The BeAA are among a limited number of amino acids which can be 
oxidized by skeletal muscle (70,115); muscle has substantial capacity 
for the degradation of BCAA as demonstrated with isolated muscle 
preparations and perfused rat hindlimbs (reviewed in 77). Furthermore, 
the apparent oxidation of BCAA by muscle is accelerated in protein 
catabolic states such as diabetes (26,139), starvation (24,139), trauma 
(9), and perhaps by exercise (74,110,194,196) as well. The large pool 
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of inactive BCDH in muscle suggests that increases in the activity 
state of BCDH may account for accelerated BCAA catabolism observed in 
the condi tions discussed above. Kasperek et al. found that the 
activity state of muscle BCDH increased markedly during exercise and 
declined toward the ini tial value in the postexercise period (100). 
However, Wagenmakers et a1. found only a minimal change in the activity 
state of muscle BCDH during exercise or starvation (183). Different 
assays were used in these studies and both are less than ideal for the 
determination of the activity state of BCDH. 
At present there is no method in use which fulfills the "ideal" 
requirements of sampling the muscle in a manner to "trap" BCDH in its 
in vivo activity state and from a single Imlscle sample render BCDH 
soluble in a form allowing assay of both the in vivo activity and with 
appropriate manipulation the total (sum of inactive and active) BCDH 
activity. In the method of Wagenmakers and coworkers (183) BCDH 
activity was measured in two homogenates of muscle prepared in an iso-
osmotic buffer with addition of fluoride and a-chloroisocaproate to the 
sample used for in vivo activity determination but no effort was made 
to determine if a transport barrier existed for the BCKA substrate or 
if there was a difference in the two samples. In the sample containing 
fluoride (for measurement of "in vivo" activity) the tonicity is 
altered and the mitochondria are likely to be uncoupled. Hutson has 
shown that BCKA are transported by a specific transporter whose 
activity is dependent on the mitochondrial pH gradient (92) and that 
the rate of BCKA oxidation by muscle mitochondria was dependent on the 
isolation procedure and media employed (94). The method of Kasperek 
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and coworkers (100) also utilizes two homogenates, a homogenate for 
determination of initial activity was prepared with fresh muscle while 
the homogenate for total BCDH activity was prepared with frozen muscle. 
The BCDH assays were carried out in the presence of detergent (elimi-
nating the possiblity of a permeability barrier) over a 20 min period. 
As observed by Hutson (94) assays performed over this time frame can 
underestimate the true activity, even though the assay appears to be 
linearly dependent on time. 
BCDH activity is generally thought to be rate-limiting for BCAA 
degradation, since BeAT activity is much greater in skeletal muscle 
than BCDH activity and BCKA are released by muscle. Nonetheless it is 
possible that under some conditions flux through BCDH may be limited by 
BCKA production by BCAT. The BCAT reaction is freely reversible thus 
its activity in the direction of BCAA --) BCKA is determined by the 
ratio of products to reactants. Studies of purified BCAT isozyme I, 
the isozyme present in muscle (99), found that a-ketoglutarate and 
BCKA are the preferred amino group acceptors in the BCAA --) BCKA 
reac t ion (1 74) . In view of the the concentrations of the available 
substrates and their affinities for the BeAT enzyme, it was suggested 
that a-ketoglutarate is the amino group acceptor for 95% of BCAA trans-
amination in skeletal muscle (131). However in diabetes the gluta-
mate/a-ketoglutarate ratio was increased in diaphragm muscles (30), 
which could slow tansamination of BCAA due to a relative deficiency of 
amino group acceptor. This raises the possibility that in muscles from 
diabetic animals flux through BCDH may be restrained by the rate of 
transamination. 
20 
Despite the potential importance of skeletal muscle in the whole 
body metabolism of BCAA there is little information on the activity 
state of BCDH, which may be the rate-limiting enzyme for muscle BCAA 
catabolism, especially under conditions of altered BCAA metabolism. 
Furthermore since muscle is likely the principal source of circulating 
BCKA to be metabolized by other tissues, information on factors 
regulating flux through BeAT is important to understanding the degree 
of interorgan cooperativity in BCAA metabolism. The experiments 
detailed in the following chapters will address: 1) the role of 
transamination in increased BCAA oxidation by muscle in diabetes and 
fasting; 2) the activity state of BCDH in skeletal muscle; and 3) 
alterations of BCDH activity in skeletal muscle under physiolosgical 
and pathological conditions. 
Chapter II 
Catabolism of Branched-Chain Amino Acids 
by Diaphragm Muscles of Fasted and Diabetic Rats 
The contents of this chapter have been previously published in similar 
form in Metabolism 34: 702-711, 1985. 
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SUlllDary 
In vitro catabolism of branched-chain amino acids, leucine and 
valine, was investigated using diaphragm muscles from normal, strepto-
zotocin-diabetic and overnight fasted rats. Oxidation and transamina-
tion of [1- 14C]branched-chain amino acids were both stimulated to a 
similar extent by diabetes or fasting, when diaphragms were incubated 
with glucose. Transamination of leucine and valine was increased when 
diaphragms were incubated with pyruvate; stimulation of transamination 
was greatest in diaphragms from diabetic rats. Leucine and valine 
oxidation by control diaphragms was inhibited by pyruvate while it was 
unchanged or slightly stimulated in diaphragms from fasted or diabetic 
rats. Thus diaphragms from diabetic rats oxidized 2-3 fold more 
branched-chain amino acids than controls when they were incubated with 
pyruvate. The specific radioactivity of extracellular a-ketoisocap-
* roate (KIC; the product of leucine transamination) produced by 
diaphragms incubated with [1-14C]leucine was similar for all groups 
(fed, fasted or diabetic) in the presence or absence of pyruvate. 
Oxidation of [1-14C]a-KIC by diaphragms from fasted or diabetic rats, 
incubated with glucose, was the same or less than KIC oxidation by 
control diaphragms. Incubation with pyruvate inhibited KIC oxidation 
by control diaphragms to a significantly greater degree than that by 
diaphragms from diabetic or fasted rats. These data suggest: 1) Flux 
through branched-chain amino acid transaminase is limited by the 
availability of amino group acceptors in diaphragms from normal and 
* Abbreviations used in this chapter are: KIC, a-ketoisocaproate; 





rats, and to a greater extent in diaphragms from 
2) Flux through the transaminase may be a major 
accelerated branched-chain amino acid oxidation by 
diaphragms in fasting and diabetes. 3) In diaphragms of fasted and 
diabetic rats, flux through the branched-chain a-ketoacid dehydrogenase 
complex is resistant to inhibition by pyruvate, which is normally 
observed in controls. 
Introduction 
Unlike most essential amino acids, the branched-chain amino acids, 
leucine, valine, and isoleucine, are catabolized extensively by 
skeletal muscle (126,78). Oxidation of the branched-chain amino acids 
in skeletal muscle is subject to metabolite (28,139) and hormonal 
control (24, 93) . In fasting or uncompensated diabetes mellitus, the 
intracellular concentrations of branched-chain amino acids in skeletal 
muscle are increased (91,112), despite apparent acceleration of their 
oxidation under the same conditions (24,27,70,139). 
The initial steps in the catabolism of the branched-chain amino 
acids are a reversible transamination to the corresponding branched-
chain a-ketoacid (95) followed by irreversible decarboxylation of the 
a-ketoacid catalyzed by branched-chain a-ketoacid dehydrogenase complex 
(131). Skeletal muscle has high levels of branched-chain amino acid 
transaminase activity but relatively low levels of branched-chain 
a-ketoacid dehydrogenase activity (131,170). It has therefore been 
suggested that the activity of the branched-chain a-ketoacid dehydroge-
nase complex is rate-limiting for the catabolism of the branched-chain 
amino acids by skeletal muscle (28,90,131,170). The activity of this 
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enzyme complex can be regulated by the availability of co-factors (NAD, 
CoA), feed-back inhibition by the products (136,146) and by an ATP-
dependent phosphorylation-dephosphorylation cycle (57,143). Recent 
evidence suggests that the complex is in a more activated state in 
mitochondria prepared from muscles of fasted or diabetic rats than from 
fed rats (140). In muscles of diabetic or fasted rats, the glutamate/ 
a-ketoglutarate ratio is increased (30,159). This may limit the rate 
of transamination of the branched-chain amino acids since a-ketogluta-
rate is the most effective amino group acceptor for transamination 
(131). Flux through the branched-chain a-ketoacid dehydrogenase 
complex may also be limited by substrate availability since the 
intracellular concentrations of branched-chain a-keto acids are less 
than saturating for the activity of the complex (131,136,146). 
In the experiments described here we investigated the role of the 
availability of amino group acceptors in regulating the flux of the 
branched-chain amino acid carbon skeleton through the branched chain 
a-ketoacid dehydrogenase complex. Pyruvate was added to stimulate the 
formation of a-ketoglutarate through the coupled reaction of alanine 
aminotransferase (84). Furthermore, we investigated whether in intact 
diaphragms the diabetes-induced stimulation of branched-chain amino 
acid oxidation is primarily a function of accelerated transamination or 
stimulated decarboxylation of the branched-chain a-ketoacids. 
Materials and Methods 
Animal care~ Male Wistar WI(BR) rats (Charles River Laboratories, 
Wilmington, MA) weighing 80-100 g were used in these studies. Fasted 
rats were without food overn ight (18 hrs). All other animals were 
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allowed access to standard laboratory chow (Wayne Rodent Blox), and 
water ad lib. Diabetes was induced by intraperitoneal injection of 
streptozotocin (85 mg/kg) after an overnight fast. Rats were consi-
dered diabetic if their plasma glucose was greater than 300 mg/dl and 
they gained less than 1 g per day in weight. Diabetic animals were 
sacrificed 5 to 7 days after induction of diabetes. 
Experimental. Rats were sacrificed by decapitation and their 
diaphragms dissected, weighed and incubated as described previously 
(26). Quarter diaphragms (30-50 mg wet weight), were incubated in the 
balanced salt solution of Gey and Gey (68) equilibrated with 02/C02 
(95:5,v/v) pH 7.4 at 37°C, containing a complete amino acid mixture at 
concentrations found in plasma of normal, ad lib fed rats (114); thus 
the branched-chain amino acids were always present at physiological 
concentrations, 0.17, 0.2 and 0.1 roM for leucine, valine and isoleucine 
respectively. Quarter diaphragms were pre incubated 30 min in 2 ml of 
the appropriate medium, then gently blotted and transferred to a vessel 
containing 2 ml of fresh medium in which branched-chain amino or 
a-ketoacid catabolism was assessed over the following 60 min. In 
experiments where a-ketoisocaproate (KIC; 4-methyl-2-oxopentanoate; the 
ketoanalogue of leucine) served as the oxidative substrate, the 
complete amino acid mixture was not included during incubation or 
preincubation except where indicated in results. 
Oxidation and transamination of valine and leucine were determined 
by including [1_14C]L-valine or [1_ 14C]L-leucine (0.02 mCi/I) in the 
incubation medium. Following incubation 0.3 ml Hyamine hydrochloride 
was injected into small cups suspended over the medium to trap 14C02 , 
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and 0.3 ml 20% perchloric acid was injected into the medium to release 
14C02 from bicarbonate, to quantitate oxidation (decarboxylation) of 
the amino acid. Free branched-chain a-keto[1- 14C]acid release into the 
medium was estimated by suspending a fresh Hyamine hydroxide containing 
cup over the medium and injecting 0.3 ml 30% H202 into the medium, the 
latter results in oxidative decarboxylation of a-ketoacids but not 
2-amino acids (131). After each addition of Hyamine hydroxide incuba-
tion was continued for 1 hr at 37°C allow complete trapping of 14C02 _ 
14C02 trapped in Hyamine hydroxide was measured in a Beckman L8 7000 
scintillation spectrometer and corrected to 75% counting efficiency by 
automatic external standardization. Samples were counted for 10 min or 
until sufficient counts were accumulated to reduce counting error to 
less than 2%. In typical one hour incubations in glucose containing 
medium, quarter diaphragms released about 1000 cpm from [1-14C]leucine 
and about 900 cpm were released after H202 treatment. Background 
radioactivity from incubations in the absence of tissue were typically 
less than 40 cpm and less than 120 cprn, respectively. Oxidation and 
transamination rates were calculated based on the initial specific 
radioactivity of the substrate in the medium and related to the wet 
weight of the diaphragm determined before incubation. Total transami-
nation was calculated as the sum of 14C02 released after acid and after 
H202 treatment. These calculations underestimate the absolute rates of 
oxidation, transamination and KIC release, since they do not take into 
account tracer dilution by intracellular substrate. The isotopic 
measurements are presented in this manner because the specific radio-
activities of the precursor pools were not determined in all experi-
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ments. However, studies where the specific radioactivity of KIC 
released by the diaphragm and that of intracellular leucine were 
measured, we found no evidence for differences in the specific 
radioactivity of the precursor pools among treatment groups (see 
Results and Discussion). 
Initial experiments established that oxidation and transamination 
of [l-14C]leucine by diaphragms from normal or diabetic rats were 
essentially linear when incubated up to 120 min. Additionally, after 
30 min of preincubation, oxidation and transamination rates were 
constant during each of three successive 30 min incubation periods 
suggesting that isotopic steady-state was achieved and maintained over 
this time period. Oxidation and transamination of leucine were also 
found to be independent of glucose concentration when 5.5 or 16.5 roM 
glucose was included in the incubation medium. 
In experiments to determine the specific radioactivities of leucine 
and KIC, hemidiaphragrns were incubated in 2.5 ml medium as described 
above, supplemented with 0.1 mM [3H]mannitol (0.5 mCi/l). The specific 
radioactivity of leucine in the medium was increased to 0.1 mCi/O.17 
mmo!/l. Diaphragms were incubated 30 or 60 min, the tissues removed, 
frozen between two blocks of dry ice and 0.5 ml of 25% (w/v) trichloro-
acetic acid was added to the media. The acidified medium samples were 
frozen at -20°C until analysis. Leucine was extracted by homogenizing 
the frozen tissue in 3 mIl g ice-cold 5% trichloroacetic acid, the 
sample was centrifuged at 12000xg for 15 min and the supernatant frozen 
at -20°C until analysis. Specific radioactivities of leucine and 
a-ketoisocaproate were determined using high performance liquid 
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chromatography (HPLC) to separate and quanti tate the compounds; the 
corresponding eluate fractions were collected and radioactivity 
determined by scintillation counting. The equipment used consisted of 
a Perkin-Elmer Series 10 liquid chromatograph. LClO fluorescence 
detector (370nm excitation, >418nm emission filter), LCI-lOO integra-
tor, and "3x3"CI8 reversed phase column preceded by a 2cmx2.1nun i. d. 
preeolumn containing C1S reversed phase packing .. The derivatization 
and separation methods for leucine and a-ketoisocaproate were adapted 
from Wassner and Li ( 190) and Kieber and Mapper (103), respectively. 
Briefly, for leucine the o-phthalaldebyde derivative was prepared and 
immediately chromatographed using a solvent program of 3 min isoeratic 
with 76% 0.05 M Na-citrate, pH 5.6/12% acetonitrile/12% 2-propanol, a 
linear gradient to 50% Na-citrate/25% acetonitrile/25% 2-propanol over 
1 min, 1.5 min isocratic at this composi tion followed by a linear 
gradient to the initial solvent composition over 2 min. Leucine eluted 
at 4.5 min and was quantitated by comparison to an external standard. 
KIC was determined as the quinoxalinol derivative prepared using _ 
a-phenylenediamine. The solvent program consisted of 3 min isocratic 
with 75% Na-citrate, pH 5.6/15% acetonitrile/l0% 2-propanol followed by 
a linear gradient to 10% Na-citrate/ 80% acetonitrile/10% 2-propanol 
over 3 min; this condition was maintained isocratic for 0.5 min then a 
linear gradient (2 min) to the starting conditions was run. KIC eluted 
at 3.7 min and was quantitated using an external standard. Preliminary 
experiments established that recovery of radiolabelled leucine or KIC 
was quantitative using these methods. Incubation with muscle did not 
significantly alter the concentration or specific radioactivity of the 
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medium leucine; KIC concentrations in the medium ranged from 0.002 to 
0.012 roM with the limit of detectability being 0.0005 mM. In calcula-
tions of intracellular leucine specific radioactivity, it was assumed 
that the medium was at equilibrium with the extracellular space in 
which mannitol and extracellular leucine were distributed identically. 
Oxidation of KIC (0.01-0.50 mM) was determined using a-keto[l-
14C] isocaproate (0.02 mCi/l) prepared from [1-14C]leucine as described 
previously (120). Oxidation of glucose was determined using [U_ 14C]-
glucose. 14C02 was trapped as described above and calculations were 
based on the initial specific radioactivity in the medium. 
Sourc.es of Materials . Radioactive amino acids, glucose and manni tol 
were from New England Nuclear (Boston, MA) or ICN Chemical and Radio-
isotope Division (Irvine, CA). Sodium a-ketoisocaproate was from 
Aldrich Chemical Company, Milwaukee, WI. Sodium pyruvate was from 
Boehringer Mannheim, Indianapolis, IN. L-amino acids, aminooxyacetic 
acid, and CIS reversed-phase column packing were from Sigma Chemical 
Company, St. Louis, MO; Hyamine hydroxide from Research Products 
International, Mount Prospect, IL. Streptozotocin was kindly supplied 
by Dr. William Dulin of Upjohn Research Laboratories, Kalamazoo, MI. 
HPLC grade solvents, and other chemicals were from Fisher Scientific, 
Norcross, GA. 
Statistics. Tabulated values are means ± S. E. M. Differences 
between mean values were determined by Student's t test (two-way). 
Differences between ratios were determined by a Mann-Whitney rank order 
test. Multiple comparison analyses were performed using the Peritz F 
test (80). Significance was assigned at p < 0.05. 
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Results 
Catabolism of leucine and valine by diaphragms of normal and diabetic 
rats. 
Diaphragms from diabetic rats, incubated in glucose containing 
medium, produced 25-50% more 14C02 from 0.17mM [1-14C]leucine than 
did control diaphragms (Table 1). Total transamination by diabetic 
diaphragms incubated in glucose was 33% greater than transamination by 
normal diaphragms (Table 1). The ratio of leucine oxidation to total 
transamination, in glucose containing medium, was the same (about 
65%) for diaphragms from normal or diabetic rats (Table 1). Using 0.20 
mM [1- 14C]valine, 14C02 production by control or diabetic diaphragms 
was similar while transamination by diabetic diaphragms was 30% greater 
than by control diaphragms when both were incubated in glucose contain-
ing medium (Table 1). 
Effects of pyruvate on the catabolism of leucine and valine. 
If the rate of leucine transamination is limited by the glutamate 
la-ketoglutarate ratio then addition of pyruvate would be expected to 
stimulate leucine transamination by its effect on glutamate-pyruvate 
aminotransferase. In pyruvate containing medium (Table 1) transamina-
tion of leucine was increased 60% in normal diaphragms and 110% in 
diabetic diaphragms when compared to glucose containing medium. 14C02 
production from leucine by normal diaphragms was inhibited about 40% in 
pyruvate containing medium while in diabetic diaphragms it was 
stimulated by about 40%. The ratio of oxidation/transamination 
decreased in the presence of pyruvate in the control and the diabetic 
group, but less in the latter. Thus, when incubated with pyruvate, 
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diaphragms from diabetic rats transaminated 80% more leucine and 
oxidized 200% more leucine than the controls (Table 1). The effects 
of pyruvate on oxidation and transamination of valine were similar to 
those observed wi th leucine but the magni tude of the effects was 
smaller (Table 1). 
An IS-hour fast affected leucine metabolism similarly to diabetes. 
When diaphragms were incubated in glucose containing medium, fasting 
increased leucine transamination more than 14C02 production from 
leucine (Table 1). The effect of pyruvate on leucine catabolism by 
diaphragms from fasted rats was qualitatively similar to that observed 
in diaphragms from diabetic rats (Table 1). Incubation with pyruvate 
stimulated transamination of leucine by fasted diaphragms 60% compared 
to glucose containing medium; oxidation of leucine was stimulated 
slightly and the amount of a-ketoacid released was increased more than 
2-fold. Diaphragms from fasted rats therefore oxidized only 30% more 
leucine than fed controls during incubation with glucose, while they 
oxidized 100% more than the controls when incubated in pyruvate. 
To assess possible effects of fasting, diabetes and pyruvate on 
the specific radioactivity of the intracellular leucine pool available 
for transamination and subsequent oxidation, the ratio of the specific 
radioactivities of extracellular KIC and extracellular leucine was 
determined. The specific radioactivity of extracellular KIC in 
perfused rat hindlimbs (93) and of plasma KIC in rats infused with 
leucine (109) was previously found to closely approximate the intracel-
lular specific radioactivity of leucine in muscles. As shown in Table 
2, although the specific radioactivity of extr~cellular KIC was less 
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than the specific radioactivity of the extracellular leucine pool 
(range 0.49 to 0.64 of leucine specific radioactivity) there was no 
significant difference after 30 or 60 min incubation between any of 
the groups. 
KIC release by incubated diaphragms was calculated from direct 
measurements (by HPLC) of KIC concentrations in the medium (Table 2). 
The values for KIC release over 60 min are about 2-fold higher than 
those estimated radioisotopically based on the specific radioactivity 
of leucine in the medium (Table 1). This is consistent with the value 
of 0.57 ± 0.02 (overall mean for 65 observations) obtained for the 
ratio of extracellular KIC to extracellular leucine specific radioact-
ivities. 
In experiments of identical design to those in Table 2, the 
specific radioactivity of intracellular leucine was measured; multiple 
comparison analysis of the ratios of the specific radioactivities of 
intracellular and extracellular leucine found no significant difference 
between the values obtained from diaphragms of fed, fasted or diabetic 
rats incubated with glucose or glucose + pyruvate, nor were there 
differences between measurements obtained after 30 or 60 min incuba-
tion. The overall mean of the ratios of the specific radioactivities 
of intracellular and extracellular leucine was 0.59 ± 0.04 (n = 73) 
which is not different from the ratio of the specific radioactivities 
of extracellular KIC and extracellular leucine (0.57 ± 0.02). 
Oxidation and transamination of valine at normal physiological 
concentration by diaphragms of normal fed rats, when incubated in 
lactate or a mixture of pyruvate and lactate (1.1 mM and 4.4 roM, 
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respecti vely) , were similar to the values obtained wi th diaphragms 
incubated in equimolar glucose (Table 3). Compared to glucose contain-
ing medium, the ratio of oxidation to transamination was decreased in 
the presence of lactate (0.64) and was lowest in the pyruvate-lactate 
mixture (0.56). These values, however, are still much greater than the 
ratio of oxidation to transamination (0.30) observed with medium 
containing 5.5 mM pyruvate (Table 1). 
Effect of pyruvate on oxidation of a-keto-[1- 14C]isocaproate. 
Since the data (Table 1) suggested that pyruvate may have a 
differential effect on the oxidation of branched chain a-ketoacids by 
diaphragms of normal fed and fasted or diabetic rats, the effect of 
pyruvate on 14C02 production from [1_ 14C]KIC was studied (Table 4). 
Values for KIC oxidation using 0.01 or 0.05 rnM KIC (near physiological 
concentrations; 91) should estimate flux through the branched-chain 
a-ketoacid dehydrogenase complex while oxidation using O.5mM KIC (close 
to the saturating concentration for oxidation of KIC by rat diaphragm; 
186) may serve as an indicator of enzyme activity, if it can be assumed 
that enzyme activity rather than transport limits oxidation. In 
glucose containing medium, 14C02 production by diaphragms of fasted or 
diabetic rats tended to be lower than that by muscles of fed controls, 
regardless of the concentration of KIC, although there was no signifi-
cant difference between groups in some experiments (Tables 4-6). 
Diaphragms from fed controls incubated in pyruvate or glucose + 
pyruvate oxidized 42-67% less KIC than those incubated with glucose, 
at all KIC concentrations tested (0.01-0.5 roM). In diaphragms from 
diabetic and fasted rats, pyruvate inhibited the oxidation of KIC 
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significantly less than in controls. At the highest KIC concentration 
tested (0.5 mM), 14C02 production by diabetic diaphragms was identical 
in glucose or in pyruvate while at lower concentrations of KIC, 
pyruvate caused slight inhibition of 14C02 production by diaphragms of 
diabetic or fasted rats in some experiments. During incubation with 
pyruvate, diaphragms from diabetic and fasted rats oxidized 40-80% more 
KIC than controls when this substrate was at low, physiological 
concentrations (0.01-0.05 roM), but oxidation rates were identical in 
the two groups at 0.5 mM concentrations of the branched-chain 
a-ketoacid. Inclusion of normal physiological concentrations of all 
the amino acids did not affect KIC oxidation significantly under any 
condition tested. 
Since the estimates of KIC oxidation could be biased by dilution 
of the 14C-labelled substrate with unlabelled KIC produced by trans-
amination of endogenous leucine, 14C02 production from 0.05 mM 
[1_14C]KIC was measured in the presence of arninooxyacetate (Table 5), 
an inhibitor of aminotransferases (88). These experiments were 
conducted using 0.05 mM KIC in order to assess oxidation at near 
physiologic substrate concentration and to avoid activation of the 
branched-chain a-ketoacid dehydrogenase which has been observed with 
higher concentrations (0.5 mM) of KIC (33,193). In glucose containing 
medium, 14C02 production by diaphragms of normal or diabetic rats was 
similar and was stimulated by about 80% in the presence of aminooxy-
acetate. Pyruvate caused about 65% inhibition of 14C02 production in 
control diaphragms and significantly less (about 35%) in diabetic 
diaphragms. 14C02 production in pyruvate containing medium was 
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slightly stimulated (about 30%) in the presence of aminooxyacetate but 
this effect was not significant in diaphragms from either control or 
diabetic rats. 
The activity of branched-chain a-ketoacid dehydrogenase complex in 
several tissues (e.g. heart. muscle. liver, kidney, and adipose tissue) 
is regulated by an ATP-dependent phosphorylation-dephosphorylation 
cycle (for review see 150) • therefore the effect of the uncoupler 
2,4-dinitrophenol on 14C02 production from 0.05 roM KIC was tested 
(Table 6). Addition of dinitrophenol stimulated 14C02 production from 
KIC by 65% in diaphragms of fed rats regardless of the presence of 
pyruvate and in diaphragms of fasted rats when incubated in glucose 
alone. In the presence of pyruvate, addition of dinitrophenol 
stimulated 14C02 production in fasted diaphragms by 37%. The relative 
inhibition of 14C02 production by pyruvate in diaphragms of fed rats 
(about 60%) was constant in the presence or absence of dinitrophenol. 
The inhibitory effect of pyruvate in diaphragms of fasted rats was 30% 
in the absence of dinitrophenol and 40% in its presence. In parallel 
experiments this concentration of dinitrophenol was found to stimulate 
oxidation of [U_ 14C]glucose ten-fold in fasted and control diaphragms 
(data not shown). indicating that 0.1 mM dinitrophenol uncoupled 
respiration in the diaphragms. 
Discussion 
These data are in agreement wi th previous studies showing that 
apparent oxidation of leucine by skeletal muscle is increased in 
diabetes and fasting (27,70,139). Transamination of leucine was 
increased in diaphragms from diabetic and fasted rats despite the 
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increased glutamate/a-ketoglutarate ratio (30,159). Since the propor-
tion of available transamination product of leucine which was oxidized 
was unchanged in diabetes and fasting, the amount of free a-keto acid 
available for export was elevated in fasting and diabetes. The studies 
of Hutson et ale (93) in perfused hindlimbs of rats, found increased 
branched chain a-keto acid export in fasting. 
The data presented here and studies of cultured myocytes (167) 
indicate that the intracellular specific radioactivity of leucine is 
less than the specific radioactivity in the medium. We found no 
evidence to suggest differences in the dilution of labelled substrates 
by intracellular pools among diaphragms from fed, fasted or diabetic 
rats or that pyruvate affected leucine distribution. In diaphragms 
incubated without insulin, protein synthesis is depressed and net 
protein degradation prevails. In two studies from our laboratory, net 
protein degradation by diaphragms from diabetic rats incubated without 
insulin was found to be the same as that by diaphragms from normal rats 
when determined as tyrosine release (30) or slightly increased when 
determined as leucine release (27). The intracellular concentration 
of leucine in diaphragms from normal and diabetic rats was the same 
after preincubation as was the specific radioactivity of intracellular 
leucine in diaphragms incubated with [l-14C]leucine, in agreement with 
the present study. Based on values for leucine release by incubated 
diaphragms previously obtained in our laboratory (27), the relative 
dilution of the medium leucine by leucine released from quarter 
diaphragms would be negligible and possible differences in the release 
of leucine/mg tissue would be offset by the diminished weight (about 
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20% less) of the diaphragms obtained from diabetic rats. Thus we would 
not expect the results to be biased by dilution of the medium branched-
chain amino acid pool with endogenous branched-chain amino acids 
supplied by protein degradation. Since the intracellular specific 
radioactivity of leucine was lower than that of the medium, the values 
shown in the Tables, based on the specific radioactivity of leucine in 
the medium, underestimate the actual rates of leucine transamination 
and oxidation. This is further supported by the finding that KIC 
release by diaphragms was greater in the experiments where it was 
measured directly by HPLC (Table 2), than in experiments where it was 
estimated radioisotopically (Table 1). Qual i tati vely the effects of 
pyruvate, fasting and diabetes on KIC release were identical, using 
either method of analysis. Since neither fasting nor diabetes, nor the 
presence of pyruvate or glucose affected the specific radioactivity of 
released KIC or of intracellular leucine, the relative changes observed 
in transamination and oxidation in response to the experimental 
manipulations seem valid. Since substrate specific radioactivities 
were not measured in all experiments, for consistency, the values for 
oxidation and transamination were not corrected but were based on the 
medium specific radioactivity of the added substrate. 
The marked stimulation of leucine and valine transamination when 
diaphragms were incubated with 5.5 mM pyruvate suggests that transami-
nation of the branched-chain amino acids is restrained by the availa-
bility of endogenous amino group acceptors. In the presence of glucose 
or when excess amino group acceptors were provided, intact diaphragms 
from diabetic and from fasted rats transaminated significantly more 
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leucine than those of fed controls, suggesting that the amount or 
activity of the transaminase is increased under these conditions; the 
effect of diabetes was greater than that of the short fast. Adibi et 
al. (3) reported that leucine aminotransferase activity in muscle 
homogenates increased with the duration of fasting. Our data suggest 
that increased flux through the transaminase resulting from increased 
transaminase activity and/or elevated branched-chain amino acid 
concentrations may be a major determinant of accelerated branched-chain 
amino acid oxidation in fasting or diabetes, due to increased substrate 
supply to the branched-chain a-ketoacid dehydrogenase complex. 
The measurements of KIC oxidation may be complicated by differences 
between the medium and intracellular specific radioacti vi ties. It 
seems likely that the relative values of KIC oxidation are valid since 
the presence of physiological concentrations of exogenous leucine, 
which readily enters the intracellular KIC pool, did not significantly 
affect the apparent KIC oxidation (Table 4). As for leucine, at low 
KIC concentrations, the actual oxidation rates are probably greater 
than those estimated from the extracellular specific radioactivity. At 
high concentrations of KIC in the medium, the contribution of intracel-
lular leucine to the KIC pool was presumably negligible. The increa-
sed 14C02 production from [l_14C]KIC in the presence of aminooxyacetate 
also suggests that intracellular KIC specific radioactivity was lower 
than that of KIC in the medium (at low KIC concentration), presumably 
due to dilution by KIC arising from endogenous leucine. Alternative 
mechanisms which may contribute to the observed stimulation of 14C02 
production include decreased flux of intracellular KIe (both 12C and 
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14C) into the intracellular leucine pool (by inhibiting reverse 
transamination) as well as metabolic effects other than inhibition of 
branched-chain amino acid transaminase; e.g. blockade of the malate-
aspartate shuttle altering the intramitochondrial redox potential 
(164). 
Wagenmakers and Veerkamp (187) have noted a differential effect of 
aminooxyacetate on oxidation of KIC by diaphragms of normal rats and 
rats fasted for 3 days. They suggest that estimates of KIC oxidation 
in diaphragms from fasted rats are greater than the true rate of KIC 
oxidation due to intracellular compartmentation of the precursor pool. 
As regards the present study, Wagenmakers and Veerkamp did not 
demonstrate a differential effect of aminooxyacetate on KIC oxidation 
by diaphragms from rats fasted for one day and the magnitude of 
increase in oxidation and transamination of leucine in the diaphragms 
from one-day fasted rats were similar to our observations in overnight 
fasted rats (Table 1). Furthermore, the apparent stimulation of KIC 
oxidation by aminooxyacetate in diaphragms from normal or diabetic 
rats was similar in the present studies. Thus we have no evidence to 
suggest that our estimates of KIC oxidation are biased by intracellular 
compartmentation. 
In our studies, during incubation with glucose, oxidation of 
physiological concentrations of KIC by diaphragms from fasted or 
diabetic rats was not increased and at the highest KIC concentration 
tested (0.5 mM, which may activate the branched-chain a-ketoacid 
dehydrogenase complex (193) but minimizes pool dilution), 14C02 produc-
tion by diabetic diaphragms was significantly less than that by 
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normals. Thus in intact diaphragms t incubated with glucose, we were 
unable to obtain evidence for increased flux through the branched-chain 
a-ketoacid dehydrogenase complex associated with diabetes, at any KIC 
concentration tested. Alterations of KIC transport across the cell 
membrane or into the mitochondria or changes in the level of cyto-
plasmic inhibitor(s) of branched-chain a-ketoacid dehydrogenase 
complex (131,141) may have prevented a reflection of altered enzyme 
activation state in flux measurements. 
It has recently been reported that the activation state of the 
branched-chain a-ketoacid dehydrogenase in diaphragms is increased 
during incubation (183) with a concomitant decrease in the total 
amount of complex present in the muscle. The present studies have not 
determined the activation state of the branched-chain a-ketoacid 
dehydrogenase complex or total enzyme activity; if there were any 
changes during incubation, they were not reflected in flux measure-
ments, which were linear over the time period investigated. 
The inhibitory effect of pyruvate on leucine oxidation in muscle 
and its resistance to inhibition by pyruvate in diaphragms of diabetic 
rats has previously been observed in our laboratory (27,28). Pyruvate 
induced inhibition is not mediated by increased a-ketoglutarate since 
previous studies found that leucine oxidation was stimulated when 
diaphragms were incubated in vitro with 1-5 mM a-ketoglutarate (28). 
The present data suggest that in diabetes or fasting the branched-chain 
a-ketoacid dehydrogenase complex is resistant to pyruvate induced 
inhibition. Studies of perfused hearts (193) and isolated heart 
mitochondria (22) indicate that addition of pyruvate results in a 
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modification of branched-chain a-ketoacid dehydrogenase which persists 
when the complex is solubilized and reduces its activity. The inabil-
ity of dinitrophenol to prevent inhibition of KIC oxidation by pyruvate 
suggests that pyruvate induced inhibition may not be mediated solely 
by ATP-dependent phosphorylation of branched-chain a-ketoacid dehydro-
genase (140). The apparent resistance of branched-chain a-ketoacid 
dehydrogenase to inhibi tion by pyruvate in muscles of diabetic and 
fasted rats may be a reflection of increased activation state of the 
enzyme (140), although we have no direct evidence for such activation. 
The mechanism causing pyruvate resistance is not clear. The role of 
pyruvate in regulating branched-chain amino acid catabolism under 
physiological and pathological conditions, i.e. exercise and diabetes, 
needs further evaluation, since the concentration of pyruvate in muscle 
during exercise can attain the concentrations used in these studies 
(50). 
Our data emphasize the complexity of regulation of branched-chain 
amino acid catabolism. Earlier studies implicated the branched-chain 
a-keto acid dehydrogenase complex as rate-limiting for branched-chain 
amino acid degradation in muscle (131,170). The present results 
suggest that under certain conditions flux through either the branched-
chain amino acid aminotransferase or through branched-chain a-ketoacid 
dehydrogenase complex can limit their rate of degradation. Further-
more, it is remarkable that despite the increased NADH/NAD and acyl 
CoA/CoASH ratios in diabetes and fasting (71,75) the apparent flux of 
leucine carbons through the branched-chain a-ketoacid dehydrogenase 
complex is not inhibited but accelerated. The enzyme complex is 
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largely in the inactive (phosphorylated) state in skeletal muscle from 
normal or fasted rats (137,184), but direct measurements of the 
phosphorylation state of the complex in muscles from diabetic animals 
remains to be accomplished (137,150). At present it is unclear whether 
the effects of diabetes and fasting on branched-chain amino acid 
catabolism result from insulinopenia and/or alterations in the metabo-
lic milieu; addition of insulin to diaphragms of diabetic rats 
incubated in vi tro does not reduce leucine oxidation (27). In this 
context it is noteworthy that a factor which activates pyruvate 
dehydrogenase kinase is present in heart mi tochondria prepared from 
diabetic or fasted rats thus rendering the pyruvate dehydrogenase 
complex refractory to activation by pyruvate (89,101). Further studies 
are needed to elucidate how diabetes and fasting prevent pyruvate 
induced inhibition of branched-chain a-keto acid oxidation, e.g. is 
mitochondrial transport of pyruvate inhibited (104) or is the branched-
chain a-ketoacid dehydrogenase complex or one of its modifiers affec-
ted. 
Table 1 Legend. 
Quarter diaphragms were incubated in medium containing 5.5mM glucose or 5.5mM pyruvate; 
oxidation and transamination of either 0.17mM [1-14C]leucine or 0.20mM [1-14C]valine were 
determined by 14C02 release as described in the Experimental section. Comparisons for dia-
phragms of diabetic and fasted rats were made to fed control values obtained with concurrently 
incubated diaphragms rather than the pooled means which are shown. 
* All values were calculated based on the initial specific radioactivity of the amino acid 
substrate in the medium and are underestimates, since the intracellular specific radioactivity 
was uniformly lower than in the medium (see Table 2 and Results). a p < 0.01 vs glucose medium; 
b p < 0.05 vs. control rats; C p < 0.001 vs. control rats; d p < 0.05 vs. glucose. 
Table 1, Cat.bolls. of leucine and valine by diaphragms from fed or fasted normal rats and from 
fed diabetic rats. 
* 14 pmal C02 / hr per mg wet weight 
Acid Release H202 Release Total Oxidation 
Group Medium "Oxidation ll "Free a-ketoacid" "Transamination" Transamination n 
Leucine 
Fed Glucose 160 ± 8 87 ± 6 247 ± 10' 0.65 ± 0.02 21 
Pyruvate 92 ± 6a 304 ± 20a 396 ± 20a 0.24 ± 0.03 13 
Diabetic Glucose 202 ± lIb 126 ± 11 c 328 ± 16c 0.62 ± 0.03 15 
Pyruvate 208 ± 19d ,c 408 ± 24a ,b 688 ± 29a ,c 0.41 ± 0.02 9 
Fasted Glucose 176 ± 19b 127 ± ISh 304 ± 27 b 0.58 ± 0.04 5 
Pyruvate 193 ± 13c 285 ± 34a 477 ± 31 a ,b 0.41 ± 0.04 5 
Valine 
Fed Glucose 135 ± 11 82 ± 8 216 ± 16 0.62 ± 0.03 10 
Pyruvate 93 ± 7d 222 ± 16a 314 ± 20a 0.30 ± 0.02 10 
Diabetic Glucose 153 ± 11 126 ± 16a 279 ± 22b 0.56 ± 0.04 6 
Pyruvate 185 ± 23 c 339 ± 37a ,b 524 ± 3Sa ,c 0.36 ± 0.04 6 
~ 
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Table 2. Specific radioactivity of extracellular a-ketoisocaproate released by diaphragms 








KIC Specific Radioactivity 
Leu Specific Radioactivity 
30 min 60 min 
0.49 ± 0.04 (7) 0.61 ± 0.03 (8) 
0.62 ± 0.08 (8) 0.62 ± 0.06 (7) 
0.56 ± 0.10 (5) 0.52 ± 0.09 (4) 
0.59 ± 0.03 (5) 0.55 ± 0.03 (3) 
0.56 ± 0.11 (5) 0.55 ± 0.06 (4) 
0.48 ± 0.04 (5) 0.67 ± 0.06 (4) 
KIC Release 
pmol/60 min per 
mg wet weight 
187 ± 13 
509 ± 45a 




800 ± 40a ,b (4) 
255 ± l1 b (4) 
507 ± 60a (4) 
Hemidiaphragms were incubated in medium containing 5.5 mM glucose or 5.5 mM pyruvate with 
0.17 roM [1_ 14C] leucine. After 30 min or 60 min incubation diaphragms were removed from the 
medium and quickly frozen. The concentrations of leucine and KIC in the medium (extracellular) 
were determined by HPLC and the specific radioactivities calculated as described in the Experi-
mental section. a p < 0.01 vs glucose; b p < 0.05 vs control. 
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and pyruvate on the catabolism of valine 
by diaphragms from fed rats. 
prool)'C 14C02/hr 
per mg wet weight 
Oxidation Transamination 
151 ± 7 218 ± 12 
165 ± 17 257 ± 22 
135 ± 14 241 ± 24 
Oxidation 
0.69 ± 0.01 
0.64 ± 0.02a 
0.56 ± O.02b ,c 
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Quarter diaphragms were incubated in medium with 5.5mM glucose or 
5.5mM lactate or 1. ImM pyruvate and 4. 4mM lactate. Oxidation and 
transamination of O.20mM (1-14C]valine was determined by 14coZ release 
as described in the Experimental section. Values shown are the means 
of five observations. 
'* Values were calculated as in Table 1 based on the initial specific 
radioactivity of valine in the medium. 
a p < 0.05 versus glucose medium 
b p < 0.01 versus glucose medium 
c p < 0.025 versus lactate medium 
Table 4 Legend. 
14C02 production from a-keto[l-14C]isocaproate by quarter diaphragms incubated in 5.5mM 
glucose was compared to 14C02 production during incubation with 5 roM pyruvate (in experiments 
with diabetic rats) or 5.5 roM glucose + 5 roM pyruvate in experiments with fasted rats. Fed 
controls were studied in both series: since the effects of pyruvate in the presence or absence 
of glucose were identical, the data in fed controls were pooled. Incubations included normal 
physiological concentrations of all the serum amino acids (86) where noted. 
calculated as in Table 1 based on the specific radioactivity of KIC in the medium. 
a p < 0.005 versus glucose; b p < 0.05 versus glucose; C p < 0.05 versus fed rats. 
'1{ 
Values were 

























* 14 pmol CO2 I hr per mg wet weight 
Glucose 
medium 
39 ± 4 
337 ± 46 
331 ± 51 
4152 ± 508 
3440 ± 359 
24 ± 4c 
264 ± 36 
228 ± 24c 
2468 ± 425 
1988 ± 226c 
]] ± 4 
230 ± 29c 
Pyruvate 
medium 
12 ± la 
106 ± 12a 
108 ± 11 3 
2324 ± 301 a 
1899 ± 253a 
20 ± 4c 
193 ± 34c 
154 ± 20b•c 
2468 ± 306 
1825 ± 190 
20 ± 2b•c 
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Table 5. Effect of aminooxyacetate on the oxidation of 










per mg wet weight 
Normal Rats 
320 ± 39 
582 ± IOOa 
110 ± 20b 
146 ± 17b 
Diabetic Rats 
353 ± 10 
627 ± 4Sa 
229 ± 45b,c 
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Quarter diaphragms from fed normal or diabetic rats were incubated in 
medium containing 5mM glucose or 5mM glucose + 5mM pyruvate, in the 
presence or absence of ImM aminooxyacetate. Oxidation of o. 05mM 
a-keto[l-14C]isocaproate was determined by 14C02 · release as described 
in the Experimental section. Values are the means for 4 or 5 observa-
tions. * Values were calculated as in Table 1 based on the specific 
radioactivity of KIe in the medium. a p < 0.001 versus no aminooxy-
acetate; b p < 0.05 versus glucose; c p < 0.05 versus control rats. 
Table 6. Effect of 2.4-dinitrophenol on the oxidation of 
















per mg wet weight 
206 ± 34 
347 ± 3Sa 
79 ± 6h 
132 ± 13b,c 
163 ± 25 
269 ± 43a ,d 
116 ± 9d 
160 ± l1 a ,b,d 
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Quarter diaphragms were incubated in medium containing 5. 5mM glucose 
or 5. 5mM glucose + 5mM pyruvate as descri bed in the Experimental 
section. Oxidation of 0.05mM a-keto[1-14C]isocaproate was determined 
as 14C02 release in the presence or absence of O.lrnM 2,4-dinitrophenol. 
Values are the means of six observations. * Values were calculated 
as in Table 1 based on the specific radioactivity of KIC in the medium. 
a p < 0.05 versus no dinitrophenol; b p < 0.02 versus glucose; 
c p < 0.005 versus no dinitrophenol; d p < 0.02 versus fed rats. 
Chapter III 
Leucine and Isoleucine Activate Skeletal MUscle 
Branched-Chain a-Keto Acid Debydrogenase In Vivo 
The contents of this chapter have been previously published in similar 




The response of rat skeletal muscle branched-chain a-ketoacid 
dehydrogenase to administration of branched-chain amino acids in vivo 
was determined using a soluble preparation of the enzyme. After 
detergent extraction of the complex in the presence of kinase and 
phosphatase inhibitors, initial in vivo activity was typically 1 nmol/ 
min/g muscle, with 0.1 roM a-keto[1-14C]isocaproate as substrate. Total 
activity of the dephosphorylated complex, measured after preincubation 
with 15 roM Mg2+, typically reached a maximum of 29 nmol/min/g. Thus, 
in overnight fasted rats the complex was 2-3% active. Initial activity 
increased 3-5 fold after leucine or isoleucine (at higher concentra-
tions) but not valine administration in vivo. After intravenous 
leucine injection (0.25 mmol/kg) initial muscle enzyme activity 
increased rapidly and subsequently declined, paralleling plasma 
leucine concentrations, while plasma valine and isoleucine declined. 
Conclusions: Muscle branched-chain a-keto acid dehydrogenase complex is 
rapidly activated when circulating leucine is increased to concentra-
tions which may occur after meals. During hyperleucinemia accelerated 
valine and isoleucine degradation by muscle may account for the 
observed "antagonism" among the branched-chain amino acids. 
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Introduction 
Skeletal muscle has been considered an important site for the 
disposal of the branched-chain amino acids (BCAA)* since the early 
studies of Miller (136) in eviscerated rats. Studies of the oxidation 
of BCAA by skeletal muscle have found high activities of the BCAA 
transaminase but quite low activities of branched-chain a-keto acid 
dehydrogenase complex (BCDH) EC 1.2.4.4 (77,131,150). BCDH catalyzes 
the first conunitted step in BCAA degradation, and is regulated by a 
phosphorylation-dephosphorylation cycle analogous to that of pyruvate 
dehydrogenase ( reviewed in 150). In homogenates of skeletal muscle 
from fed or fasted rats only a small fraction of the BCDH complex was 
in the active state and was essentially unresponsive to physiological 
manipulations (184,185). However, Kasperek et ale (100), using deter-
gent-treated homogenates, recently reported marked activation of 
skeletal muscle BCDH by exercise. Studies of muscle homogenates (184, 
185) and isolated intact mitochondria (140) cannot distinguish between 
changes in mitochondrial transport and BCDH activation. Attempts to 
measure the activity state of BCDH solubilized from rat skeletal 
muscle mitochondria have been unsuccessful due in part to the low 
initial activity of the complex, but it was estimated that less than 
20% of the complex was active (77 t 137 t 150). Since several groups 
failed to demonstrate significant activation of BCDH in muscle in vivo 
'/( 
The abbreviations used in this chapter are: BCAA, branched-chain 
amino acids; BCDH, branched-chain a-keto acid dehydrogenase; PEG, 
polyethylene glycol. 
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the relative contribution of skeletal muscle to whole body BCAA 
catabolism has been questioned (77,184,200). 
Administration of leucine to rats and man results in decreased 
circulating valine and isoleucine, as well as increased valine oxida-
tion by the intact organism (reviewed in 77). Oxidation of valine by 
perfused rat hindlimbs (200) and by isolated epitrochlearis muscles 
(124) was markedly increased by the addition of increasing concentra-
tions of leucine. These results suggest that muscle BCDH may be 
activated in the presence of leucine, as reported in adipose tissue 
(64). Due to its mass, skeletal muscle contains a large pool of 
inactive BCDH which could be recruited to oxidize the BCAA in the 
presence of increased circulating BCAA, such as occurs after a protein 
meal (52,145). In this communication we describe a method to determine 
the activity state of BCDH in a solubilized preparation from skeletal 
muscle. Using this method we show for the first time rapid, in vivo 
activation of the muscle BCDH complex after administration of leucine 
and to a lesser extent isoleucine. 
Materials and Methods 
Male Wistar (WI)BR rats (Charles River Laboratories, Wilmington, 
MA) were allowed access to standard rodent chow (Wayne Rodent Blox, 
Continental Grain Co., Chicago, IL) and water ad libitum, food was 
removed 14-18 hours prior to sacrifice, between 9 and 11 AM. Rats 
receiving i. v. treatments had chronic intravenous catheters inserted 
into a jugular vein the afternoon prior to infusion, using the proce-
dure of Harms and Ojeda (76). Intravenous infusions were performed 
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with the animals under light anesthesia induced with methoxyflurane 
vapor. 
Rats were anesthetized with methoxyflurane and the hindlimb skinned 
to expose the muscles. The Achilles tendon was secured with a hemostat 
and severed, the gastrocnemius and soleus were dissected free of under-
lying tissue, frozen with metal tongs cooled in liquid nitrogen, cut 
free of their origins and immersed in liquid nitrogen until further 
processed, usually within 4 hr. The frozen muscles were powdered with 
a porcelain mortar and pestle precooled with liquid nitrogen. A sample 
of the frozen powdered muscle was weighed into a precooled glass 
homogenizer tube, 4 ml of ice-cold extraction buffer per g of tissue 
added and the slurry homogenized with 10 strokes of a motor-driven 
Teflon pestle. Extraction buffer consisted of: 100 roM KH2P04' 5% WI, 
2 roM Na2EDTA, 5 roM dithiotreitol, 0.5 mM thiamine pyrophosphate, 1 mM 
TLCK, 20 ~g/ml leupeptin, 50 mM KF, (phosphatase inhibitor), 5 mM 
dichloroacetic acid (kinase inhibitor; 143), adjusted to pH 7.4 at 4°C 
with KOH. (In preliminary studies, dichloroacetic and a-chloroiso-
caproic acids were both effective in inhibiting the kinase.) Insoluble 
material was removed by centrifugation (5 min at 27000xg), and 0.5 
volume of 27% PEG-6000 was added to the supernatant, resulting in a 
final PEG concentration of 9%. After standing 20 min on ice the 
precipitate was collected by centrifugation (10 min at 12000xg), and 
resuspended in 1 ml assay buffer per g tissue homogenized. Assay 
buffer consisted of: 25 mM Hepes, 0.2 mM Na2EDTA, 0.4 mM thiamine 
pyrophosphate, 1 mM dithiothreitol, 20 ~g/ml leupeptin, 0.1% Brij 58, 
adjusted to pH 7.4 with KOH at 37°C. 
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BCDH activity in muscle preparations was measured as 14cOZ released 
from 0.1 roM a-keto[1-14C]isocaproate (1.5 Ci/mol). Assays were 
conducted in triplicate, at 37oC, in 0.35 ml total volume of the assay 
buffer described above, supplemented with 0.5 mM CoASH, 0.5 mM NAD, and 
1.2 roM MgS04. Assays were quenched with 0.2 ml 25% trichloroacetic 
acid, 14C02 collected in 0.2 ml Hyamine hydroxide, and radioactivity 
determined by liquid scintillation spectrometry as described previously 
(6,120). Initial BCDH activity (an estimate of in vivo activity) was 
determined using the enzyme preparation from muscle directly in the 
assay described above; for measurements of total enzyme activity (an 
estimate of enzyme amount) the preparation was diluted with assay 
buffer supplemented with MgS04 (final concentration 15 mM) and pre-
incubated 60 min at 37°e to activate the complex before assay (see 
Results). The activation state of BCDH was determined as the ratio of 
initial activity to total activity. 
Blood was removed by heart puncture inunediately after removal of 
muscle samples and added to heparinized tubes. After centrifugation 
plasma samples were deproteinized by addition of 0.1 volume of 50% 
sulfosalicylic acid and stored frozen at -20oe until analysis. BCAA 
were measured by reversed-phase high-performance liquid chromatography 
separation and fluorescent detection of their o-phthalaldehyde deriva-
tives as described previously (6). 
Materials were obtained as described previously (7). WI, a linear 
polyoxyethy1ene ether detergent, and hog kidney D-amino acid oxidase 
were' obtained from Sigma Chemical Co. (St. Louis, MO). Methoxyflurane 
was obtained from Pitman-Moore, Inc. (Washington Crossing, N.J.). 
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a-Keto-[1- 14C)isocaproate was prepared from DL-[1-14C]leucine (ICN 
Radiochemicals, Irvine, CA), as described previously (120) but with the 
addition of D-amino acid oxidase~ Dr. Ronald Simpson of Sandoz 
Pharmaceuticals (E. Hanover, NJ) kindly donated a-chloroisocaproate. 
Results and Discussion 
Published methods for determining the activity state of muscle BCDH 
either did not have adequate sensitivity to determine initial activi-
ties of the complex or were complicated by membrane barriers between 
the substrate and the enzyme complex. We therefore developed a method 
to circumvent these difficulties, guided by several earlier studies 
(69,131,144). Attempts to prepare detergent extracts directly from 
skeletal muscle in the presence of detergent and inhibitors of kinase 
(dichloroacetate) and phosphatase (F-) failed to detect BCDH activity. 
Only after precipitation of the complex with PEG could we measure 
initial BCDH activity. Measurable initial activity was obtained by 
precipitation with greater than 6% PEG while the maximal rate of 
activation required about 9% PEG and diminished as the PEG concentra-
tion was increased above 12%. The recovery of measurable BCDH 
activity after PEG precipitation, as opposed to the lack of activity 
in detergent-treated homogenates, may result from concentration of the 
complex by precipitation (about 5-fold) or perhaps removal of an 
inhibitory factor from the homogenates as suggested by Odessey and 
Goldberg (131), and Paul and Adibi (141). The initial activity of the 
preparation was stable for at least 90 min when stored on ice and for 
at least 75 min when incubated at 37°C (data not shown), showing no 
evidence of activation. 
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Preincubation of the enzyme preparation with 15 mM Mg2+ at 37°C 
resulted in a time-dependent increase in the activity of the complex, 
from an initial acti vi ty of o. 7 nmal/min/ g muscle to a maximum of 29 
nmol/min/g muscle after 40-60 min of incubation; maximal activity 
remained stable until at least 80 min of incubation (Figure lA). The 
increase in activity upon incubation with Mg2+ presumably reflected 
conversion of the complex from the phosphorylated (inactive) to the 
dephosphorylated (active) form (77,137). This suggests that in 
skeletal muscle of rats fasted overnight about 2% of the BCDH was in 
the active state. Activation of the complex was unaffected by 10 ~g/ml 
protamine sulfate, 1 ~M insulin or 2 mM MnC12 (data not shown). The 
relatively high PEG concentration (9%) necessary to maximize activation 
of the complex may be due to coprecipitation of a specific BCDH 
phosphatase, although the rate of activation in our preparation was 
unaffected by protamine sulfate which activated the specific phospha-
tase purified from bovine kidney (33). 
The assay of BCDH activity was linear up to 7.5 min for initial 
BeDH activity and up to 3 min for assay of total activity after 
activation of the complex with Mg2+ (Figure IB); measurements were 
independent of the volume of enzyme preparation assayed in the range 
of Q.06 to 0.18 ml of initial enzyme preparation and 0.008 to 0.02 ml 
of enzyme preparation after activation with Mg2+ (data not shown). In 
later experiments initial activity was routinely assayed over 5 min 
using 0.15 ml of enzyme and total activity was assayed over 1 min after 
60 min preincubation with 15 roM Mg2+, using 0.025 ml of diluted enzyme 
preparation (equal parts of initial preparation and assay buffer 
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supplemented with 30 mM MgS04). BCDH activity assayed either before or 
after incubation with Mg 2+ was unchanged by the addition of lipoarnide 
dehydrogenase (data not shown). Kinetic parameters of the BCDH complex 
after activation with Mg2+ were determined from reaction velocities 
with eight substrate concentrations between 0.01 and 0.6 mM a-ketoiso-
caproate. The data were analyzed using non-linear least squares fit to 
the Michaelis-Menten equation (150) and the apparent parameters found 
to be: Km 0.09 ± 0.01 roM, Vrnax 79 ± 2 nmol/min/g muscle (mean ± SE from 
5 preparations). Due to the low activity of the enzyme preparation in 
its initial state it was not possible to determine the kinetics of the 
complex prior to activation. 
Our method of preparation of branched-chain a-keto acid dehydro-
genase may result in some loss of the complex during the precipitation 
step (133,144), thus the total amount of enzyme complex may be greater 
than our measurements indicate; losses of complex would not be expected 
to bias measurements of the activity state of the complex since samples 
for initial and total activities would be subject to the same losses. 
Despite this possibility, our measurements of the initial and total 
BCDH activity and activation state are similar to the values obtained 
by Wagenmakers et a1. in muscle homogenates (184,185) and the total 
BCDH activity obtained by Patston et a1. in detergent solubilized 
muscle mitochondria (137). The BCDH activities obtained by Kasperek 
et al. (100) are also similar to ours and other investigators (137,184, 
185) although their assay used 1 roM a-ketoisocaproate (a saturating 
concentration) while the other assays use 0.1 mM substrate (subsatura-
ting) . In light of the low values we have obtained for the initial 
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activity of BCDH, which precluded generation of kinetic data, we cannot 
distinguish between the possibilities that the initial activities 
measured represent either 1) the activity solely of a small fraction of 
active (i.e. dephosphorylated) complex or 2) that initial activity is 
comprised principally of residual activity of the phosphorylated (i.e. 
inactive complex) which could exhibit different kinetic properties. 
We first attempted to modulate the activity of BCDH in vivo by 
injecting rats i.p. with leucine or valine (2 nunol/kg) and taking 
muscle samples for the assay of BCDH complex one hour later. As shown 
in Figure 2A treatment with leucine resulted in a nearly four-fold 
increase in the activity state of BCDH (from 2.1% to 7.87.) while after 
valine treatment the activity state was the same as that in saline 
treated controls. Since the lack of effect of valine on BCDH activity 
could have been due to differences in the rate of absorption and 
clearance, we investigated the effect of i.v. administration of the 
BCAA on the acti vi ty of the muscle complex. Figure 2B shows that 
valine administration had no effect on the activity state of BCDH even 
at the highest dose tested (0.5 mmol/kg), which resulted in a 2.2 fold 
increase in the whole blood valine concentration (data not shown). 
Within 15 min of administering a large dose (0.5 mmol/kg) of isoleucine 
or leucine the complex was activated from 3% in controls to 12% and 22% 
active, respectively; whole blood isoleucine and leucine concentrations 
increased 3.5- and 1.9-fold, respectively, with these treatments (data 
not shown). With smaller doses (0.25 mmol/kg) only leucine activated 
BCDH, to about 10% active. 
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Branched-chain a-keto acids, the products of the transamination of 
BCAA, are known inhibitors of BCDH kinase, and their levels in plasma 
and muscle generally parallel those of circulating BCAA (52). Our 
results are consistent with the potency of the a-keto analogues of the 
branched-chain amino acids as inhibitors of BCDH kinase: a-ketoiso-
caproate > a-keto-a-methylvalerate » a-ketoisovalerate (107,142). 
Rapid activation of BCDH after leucine administration in our studies 
may explain the accelerated valine oxidation observed in muscles 
exposed to high leucine concentrations (124,200). 
The time course of activation of muscle BCDH by leucine is shown in 
Figure 3A. The initial activity of the complex increased rapidly 
(within 10 min) after i.v. administration of leucine, from 0.7 to 2.1 
nmol/min/g muscle (1.8% to 6.6% active complex). BCDH activity 
declined within 20 min after leucine treatment, decreasing to about 1 
nmol/min/g (about 3.3% active) at 40 min and remained unchanged at 60 
min. The changes in muscle BCnH activity with time after administra-
tion of leucine closely parallel the changes in the plasma leucine 
concentration shown in Figure 3B; plasma leucine increased from 0.165 
roM in saline controls to 0.329 mM by 10 min after leucine injection and 
then declined to the initial value at 40 min. The plasma concentra-
tions of valine and isoleucine declined steadily after leucine admini-
stration reaching a nadir at 40 min with valine concentrations depres-
sed by 25% and isoleucine concentrations depressed by 30%; no further 
change occurred at 60 min. 
The circulating concentrations of leucine which resulted in 
activation of muscle BCDH were not very great and should be easily 
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attained post-prandially after protein ingestion (52,145). Indeed, the 
activi ty of muscle BCDH responds to consumption of a meal and to the 
protein content of the diet (unpublished observations) . Thus, the 
contribution of skeletal muscle to BCAA catabolism may be markedly 
increased post-prandially. 
Feeding animals diets supplemented with excessive amounts of 
leucine results in growth impairment, increased concentrations of 
circulating leucine and depressions in valine and isoleucine; feeding 
excesses of isoleucine or valine does not result in depression of 
plasma leucine or growth impairment. This apparent antagonism among 
the BCAA has been extensively studied (for review see 77). In our 
experiments an i.v. bolus of leucine resulted in decreased circulating 
valine and isoleucine and concomitant activation of muscle BCDHj the 
activation state of BCDH appeared to parallel changes in circulating 
leucine. Thus, during hyperleucinemia, accelerated oxidation of valine 
and isoleucine by muscle may result in the observed depressions of 
these amino acids in plasma. We cannot exclude however possible 
changes in protein turnover contributing to the altered amino acid 
profile observed here after leucine injection (reviewed in 77). 
The precise role of the various tissues in branched-chain amino 
acid catabolism is not well understood. The non-uniform distribution 
of transaminase and BCDH in different tissues suggests the existence 
of interorgan cooperativity in their catabolism (reviewed in 77,150). 
In contrast to muscle, BCAA transaminase is low in liver, but BCDH is 
abundant. Hepatic BCDH in rats fed an adequate protein diet is nearly 
fully active and is not further activated by increasing the protein 
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content of the diet (69) or administering BCAA (16). We confirmed the 
latter in the present study. In the experiments shown in Fig. 2 the 
activation state of hepatic BCDH was measured as described in (4); it 
was found to be 80-83% active and unchanged after the administration of 
leucine, isoleucine, or valine. However a role for the liver in the 
disposal of excess BCAA cannot be discounted since increased branched-
chain a-keto acid export from peripheral tissues rich in BCAA trans-
am.inase may increase avai lable substrate for 1 i ver BCDH (112). 
Recent studies suggest that extrahepatic tissues (e.g. muscle) must 
contribute to the leucine induced stimulation of BCAA oxidation in vivo 
(16,77); the present observations, showing activation of the rate 
limi ting enzyme in muscle after leucine administration, support this 
hypothesis. Our method for measuring the activity state of BCDH in 
muscle should prove a valuable adjunct to studies of BCAA degradation 
and its regulation by dietary and hormonal treatments. 
Figure 1. Activation of muscle branched-chain a-keto acid 
dehydrogenase by Hg2+ and assay linearity. 
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Branched-chain a-keto acid dehydrogenase was prepared as described 
under "Materials and Methods". In panel A 0.15 ml of enzyme preparation 
was assayed for 5 min as described under "Materials and Methods" to 
obtain the zero time point. A sample of enzyme preparation was mixed 
with an equal volume of assay buffer supplemented with 30 mM MgS04 and 
incubated at 37oC; at the indicated times 0.025 rnl samples were taken 
and assayed for 1 min. Values shown are the means ± SEM from 6 enzyme 
preparations. In panel B initial (unactivated) BCDH activity (-) was 
determined using 0.15 ml of enzyme preparation and assayed for the 
times indicated. Total BCDH activity (41) was measured using 0.025 ml 
of diluted enzyme after incubation for 60 min wi th Mg 2+ as described 
above, and assays terminated at the times indicated. Results shown are 
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Figure 2. Activity state of muscle branched-chain a-keto acid 
dehydrogenase after treatment with branched-chain amino acids in vivo. 
In panel A rats were injected i.p. with leucine or valine (2 
nunol/kg) or an equal volume of saline. One hour after injection 
muscle samples were taken and initial and total BCDH activity assayed 
as described under "Materials and Methods" and Fig 1. Percent activity 
was determined as the ratio of initial activity to total activity, 
results shown are means ± SEM; 6 animals were treated with valine or 
saline and 11 with leucine. Total activities were the same for all 
groups, 18 ± 2 nmol/min/g muscle (n=23). In panel B rats were injected 
i. v. through a jugular venous catheter as described under "Materials 
and Methods" with amino acids at the dose shown or an equal volume of 
saline. Muscle samples were taken 15 min after treatment for the 
determination of BCDH activity as described above. Total activities 
were the same for all groups, 28 ± 1 nmol/min/g muscle (n=39), with 4 
to 9 animals in each group. * p < 0.05 compared to saline control; 
** p < 0.001 compared to saline control, p < 0.05 compared to 500 
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Piaure 3. Time course of muscle branched-chain a-keto acid dehydro-
genase activation and plasma branched-chain amino acid concentrations 
after leucine infusion in vivo. 
Rats were injected i.v. with 0.25 mmol/kg leucine or an equal 
volume of saline (time 0 points), muscle and blood samples were taken 
at various times after injection as indicated. A. Initial activity 
( .), total activity, and % activity (e) of branched-chain a-keto acid 
dehydrogenase were determined as described in Fig. 2B. Total activi-
ties were the same for all groups, 33.9 ± 1.3 nmol/min/g tissue 
(n = 28). B. Leucine (e), valine (.) and isoleucine (A) in plasma were 
determined as described under ttMaterials and Methods". In both panels 
values shown are the means ± SEM from 4-8 animals. * p < 0.05 
d · 0 ** p < 0.01 d· 0 compare to tlme ; compare to tlme . 
Figure 3. 
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Modulation of Rat Skeletal MUscle Branched-Chain 
a-Keto Acid Dehydrogenase In Vivo: 
Effects of Dietary Protein and Heal Consumption 
The contents of this chapter have been published in similar form in 
Journal of Clinical Investigation 79: 1349-1358, 1987. 
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SUlllllary 
The effects of dietary protein on the activity of skeletal muscle 
branched-chain a-keto acid dehydrogenase (BCDH)* were investigated. 
BCDH is rate-limiting for branched-chain amino acid (BCAA) catabolism 
by muscle; its activity is modulated by phosphorylCition-dephosphory-
lation. In rats fed an adequate protein (25% casein) diet, BCDH was 
-2% active postabsorptively and increased to 10% or 16% active after a 
25% or 50% protein meal, respectively. Feeding a 50% protein diet (10 
days) increased postabsorptive BCDH activity to 7% with further 
increases to 40% active postprandially. On a low protein (9% casein) 
diet (10 days) BCDH remained -2% active regardless of meal feeding. 
Dose-dependent activation of BCDH by intravenous leucine in postab-
sorptive rats was blunted by a low protein diet. Conclusions: Excesses 
of dietary protein enhance the capacity of skeletal muscle to oxidize 
BCAA; when protein intake is inadequate, muscle conserves BCAA; 
skeletal muscle may play an important role in whole body BCAA homeo-
stasis. 
Introduction 
Chronic consumption of high protein diets results in induction of 
rate-1imi ting degrading enzymes for most essential amino acids (79, 
106). Hence, the concentrations of most amino acids do not increase 
markedly in body fluids after long term high protein feeding and may 
actually decrease as more protein is consumed (145). When dietary 
* Abbreviations used in this chapter are: BCDH, branched-chain a-
keto acid dehydrogenase; BCAA, branched-chain amino acids; BCKA, 
branched-chain a-keto acids. 
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protein intake is restricted to less than the requirement for growth 
and maintenance, these enzymes decrease (79,106), resulting in con-
servation of essential amino acids. The catabolic system for the 
branched-chain amino acids (BCAA) - leucine, isoleucine and valine -
appears to be an exception to this homeostatic scheme for essential 
amino acids in that a) their concentrations in blood and tissues rise 
in direct proportion to the protein content of the diet (109,118,145) 
and b) BCAA aminotransferase, the initial enzyme in BCAA catabolism, is 
relatively refractory to changes in dietary protein (96). This 
apparent lack of adaptation has prompted some investigators to conclude 
that the body is unable to maintain the free body pools of BeAA by 
increasing oxidation during times of surfeit or by decreasing oxidation 
during times of deficiency. However, studies in man and rat have shown 
that BCAA oxidation in vivo is increased markedly after high protein 
feeding (109,129,182), and is severely depressed after consumption of 
low protein diets (109 t 129). The mechanisms responsible for these 
alterations in BCAA oxidation are incompletely understood. Recent 
studies suggest that fluctuations in BCAA oxidation with dietary 
manipulations cannot be explained based solely on the mass action 
principle (129a). Control of BCAA metabolism by dietary protein is 
of particular interest as branched-chain amino and keto acids are being 
used in the treatment of hepatic encephalopathy and renal insuffic-
iency, conditions in which low protein diets are usually indicated 
(19,189). 
The first connnitted reaction in the metabolism of BeAA is cata-
lyzed by branched-chain a-keto acid dehydrogenase (BCDH), a multienzyme 
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complex located on the inner surface of the inner mitochondrial 
membrane of most cells (77,150). BeDH catalyzes the irreversible 
oxidative decarboxylation of branched-chain a-keto acids (BCKA) 
a-ketoisocaproate (ketoleucine), a-keto-a-methylvalerate (ketoiso-
leucine), and a-ketoisovalerate (ketovaline) - which are formed from 
their respective BeAA through the action of BeAA aminotransferase. 
Both BCDH and BCAA aminotransferase are distributed ubiquitously but 
non-uniformly throughout the body. BCDH activity is highest in liver, 
kidney, and heart, but very low in skeletal muscle (77,150). In 
contrast, BeAA aminotransferase activity is highest in skeletal muscle 
but very low in liver (77,150). BCDH is believed to limit the rate of 
BCAA catabolism in vivo (117). 
BCDH is unusual among amino acid-degrading enzymes in that it is 
regulated by a phosphorylation (inactivation)-dephosphorylation 
(activation) mechanism similar to that which exists for the pyruvate 
dehydrogenase complex (195). As with pyruvate dehydrogenase, a protein 
phosphatase and kinase are believed to be associated with BCDH in vivo. 
Alteration of the phosphorylation state of BCDH permits rapid changes 
in enzyme activity which are not possible via an induction-repression 
mechanism (77). The physiological significance of BCDH modulation by 
phosphorylation is currently an active area of study (199). 
In normally fed rats, BCDH from liver is essentially fully active 
(i.e. dephosphorylated) (69,77,81,185). In contrast, less than 20% of 
skeletal muscle BCDH is in the active form (5,77,137,150,185). As 
skeletal muscle comprises approximately 40% of the rat's body weight 
(73), changes in the phosphorylation state of muscle BCDH could have 
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profound effects on BCAA metabolism in vivo. However, efforts to 
detect changes in the activity state of muscle BCDH in response to 
physiological manipulations have been largely unsuccessful (77,137, 
184). In view of the high BCAA aminotransferase and low BCDH activity 
of muscles, it was proposed that muscle may primarily deaminate BCAA 
and release BCKA into the circulation for eventual oxidation by liver 
where BCDH is found in abundance (77,112,150). Uncertainty about the 
role of muscle in BCAA metabolism has stenuned in part from the diffi-
culty in measuring activities of BCDH from solubilized muscle prepa-
rations (131,137,140,181). Therefore, intact muscle mitochondria were 
used in most studies to assay BCDH activity (77,140,150,184). Problems 
associated with substrate transport, quantitation of precursor specific 
radioactivity, and possible activation of the enzyme during mitochon-
drial isolation or incubation complicate interpretation of such 
studies. Recently, we described an assay for measuring BCDH in 
solubilized rat muscle tissue and showed that the enzyme was activated 
in vivo after intravenous leucine administration (5). We have used 
this assay in the present study and found that muscle BCDH is activated 
rapidly in vivo after consumption of meals containing adequate to high 
levels of protein, and that the activation state of the enzyme is 
responsive both acutely and chronically to the protein content of the 
diet. 
Materials and Methods 
Animals. Male Wistar (WI) BR rats (Charles River Laboratories, 
Wilmington, MA). initially weighing 140-160 g, were used in all 
studies. Rats were kept in a room maintained at 24°C with a reverse 12 
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hour light - 12 hour dark cycle. The dark period was from 3:00 AM to 
3:00 PM. Rats were offered their daily allotment of food within the 
last 6 hours of the dark cycle (9:00 AM - 3:00 PM). This meal-feeding 
regimen minimized variations in enzyme and metabolite measurements due 
to fluctuations in food intake (145). Water was supplied ad libitum. 
Diets and Treatments. All diets were specially prepared in pellet 
form by United States Biochemical Corp. (Cleveland, OH) and contained 
in percentage by weight: Rogers and Harper's mineral mix, 5 (155); AIN 
76 vitamin mix, 1; corn oil, 5; choline chloride, 0.2; vitamin-free 
casein, 0, 9, 25 or 50; and equal amounts of glucose monohydrate (A.E. 
Staley Manufacturing Co., Oak Brook, IL) and cornstarch (American 
Maize, Hammond, IN) to make up 100%, The 9% casein diet was supple-
mented with methionine, 0.3% (w/w) (48). 
Rats were first acclimated to the 25% casein diet ad libitum for 2 
days; then rats were trained to consume the 25% casein diet during the 
last 6 hours of the dark cycle for 2 weeks (meal-feeding). After this 
training period, both chronic and acute effects of dietary protein on 
BeAA metabolism were studied, In the chronic study, rats were meal-fed 
the 0, 9, 25 or 50% casein diets for 10 days. Body weights were 
measured each day. On the tenth day, rats were killed before or 3 
hours after presentation of the meal. Previous studies have shown that 
circulating levels of BeAA are greatest 3 hours postprandially in 
meal-fed rats (48). In the acute studies, rats previously fed the 25% 
casein diet for 2 weeks were offered a single meal containing 9, 25 or 
50% casein. Rats failed to consume a single meal of the 0% casein 
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diet, hence this group was omitted. Rats were killed before and 3. 6 
and 12 hours after presentation of the meal. 
Previous studies (17,48,145) have shown that during the first few 
days of offering an adequate protein diet for 6-8 hrs a day (meal-
feeding), food consumption is less than that of ad libitum-fed rats. 
However, food intake increases gradually and after one week, meal-fed 
and ad libitum-fed rats consume equal amounts of food. Rats maintained 
chronically on casein diets similar to those used here consume equal 
amounts of food except for those given a protein-free diet, which 
consume 43% less (17). In the present study, food intake was measured 
in the acute experiments and was not significantly different between 
rats fed 9%, 25% or 50% casein diets (14 ± 1 g/meal). 
In a separate experiment, the effects of leucine infusions on 
muscle BCDH activity were investigated in rats fed 25% or 9% casein 
diets ad libitum for 2 weeks. Rats were anesthetized with methoxy-
flurane (Metofane) after an overnight fast (5) and L-leucine was 
infused via the tail vein at doses of 0, 10, 25, 50, and 100 ~mol/100 g 
body weight. Muscles were excised 15 minutes after injections. 
BCDH Assay. Our method for determining BCDH activity in muscle 
has been described in detail previously (5,15). Briefly, the method 
involved freeze-clamping whole muscle in situ. BCDH was extracted from 
powdered frozen muscle in the presence of protease, phosphatase,. and 
kinase inhibitors and then precipitated with polyethylene glycol. 
Basal (in vivo) BCDH activities were determined irmnediately after 
redissolving the precipitated proteins and total (fully-active) enzyme 
activities were measured after preincubation of the extract at 37°C 
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with 15 mM Mg2+ prior to assay. In these studies BCDH activity was 
determined by 14C02 release from O. 1 mM Q-keto [ 1_
14C] isovalerate at 
37°C. Percentage of BCDH in the active form was calculated as the 
ratio of basal to total BCDH activities. 
Amino Acids, Protein and DNA. Heparinized plasma was deprotein-
ized by adding ice cold sulfosalicylic acid (0.1 volumes of a 50% w/v 
solution). After standing 20 minutes on ice, samples were centrifuged 
at 30, 000 X g for 10 minutes. Muscle samples were deproteinized by 
adding 4 volumes of ice cold 5.9% w/v sulfosalicylic acid to powdered 
muscle samples. Muscles were then homogenized with a Polytron tissue 
homogenizer and left on ice for 20 minutes. The mixture was then 
centrifuged at 30 J 000 X g at 4°C for 10 minutes. Plasma and muscle 
BCAA concentrations in deproteinized samples were measured using 
reversed-phase high performance liquid chromatography separation of the 
~-phthalaldehyde derivatives and fluorescent detection (6). BCAA 
concentrations (~molig) were expressed per milliliter of intracellular 
water assuming that muscle contains 80% water: 60% intracellular and 
20% extracellular, the latter at equilibrium with plasma (30). 
Muscle protein concentrations were determined according to the 
method of Lowry (113) with bovine serum albumin as the standard. 
Muscle DNA concentrations were measured using a modification of the 
Burton assay (191) with herring sperm DNA as the standard. 
Statistical analyses of differences between groups were performed 
by Student's t test or by the Peritz multiple range F test (80) and 
were considered significant if p < 0.05. Values for % active complex 
were subjected to the inverse sine transformation prior to statistical 
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analysis as percentages are distributed binomially rather than normally 
(173). This transformation is especially recommended for values in the 
range of most of the present observations (0-20%). Regression analysis 
was performed by the linear least squares method and slopes compared by 
Student's t test (173). All values shown are means ± SEM. 
Results 
BCDH Assay. As others have shown diet-mediated changes in BCDH 
activities from liver, kidney and heart (69,77,81,137,150), we first 
sought to optimize the assay for BCDH isolated from muscles of rats fed 
differing levels of protein. Rats were meal-fed 0%, 25% (normal) or 50% 
(high) casein diets for approximately 2 weeks. Muscles were excised 3 
hours after presentation of the meal. As shown in Figure 1, basal (in 
vivo) BCDH activity increased as the protein content of the diet 
increased. The assay for basal BCDH activity was linear up to 5 
minutes in all diet groups whether 100 or 150 ~1 of muscle extract was 
used. To ensure that no more than 10% of a-ketoisovalerate was 
utilized during the reaction (168), basal activities from 0% and 9% 
casein groups were routinely assayed for 5 minutes using 150 ..,.1 of 
extract. Basal BCDH activities from 25% and 50% casein groups were 
assayed for 2-5 minutes, utilizing 100 fJl of extract. Total BCDH 
activities were linear up to 3 minutes in all diet groups; therefore, 
total activities were routinely assayed over 1 minute (5,15). 
Recently, Randle and associates have shown that BeDH from liver of 
rats fed low protein diets is refractory to dephosphorylation (138). 
To investigate whether dietary protein might affect the rate of muscle 
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BCDH activation, total BCDH activities were measured 20, 40, 60 and 80 
minutes after preincubation at 37°C in a buffer containing 15 mM Mg2+. 
The time required to attain maximal BCDH activities in muscle extracts 
from rats fed diets containing 0%, 25% or 50% casein are shown in 
Figure 2. Maximal activities for rats fed the 25% or 50% casein diets 
were obtained after 40 minutes of preincubation. In contrast, maximal 
BCDH activities in muscles of rats fed the 0% casein diet were not 
obtained until 60 minutes of preincubation. This lag phase of muscle 
BCDH activation was also observed in rats fed the 9% casein diet (data 
not shown). Fully activated (total) enzyme activities (ronol/minig 
tissue) were not significantly different among the groups. 
Chronic Effects of Dietary Protein. Rats fed the protein-free diet 
failed to thrive and lost approximately 40 grams of weight during the 
10 day study (Table 1). Addition of 9%, 25% or 50% casein to the diet 
resulted in growth rates of 4-6 grams/day. Rats fed the 9% casein diet 
attained 60% of the weight gain observed in rats fed the 25% casein 
diet. Continued growth on the 9% casein diet was most probably due to 
its supplementation with methionine, the first limiting amino acid in 
casein; hence this diet constituted a protein restricted rather than an 
essential amino acid deficient diet. The changes in growth due to 
dietary protein were accompanied by alterations in the protein and DNA 
concentration in skeletal muscle (Table 1). The proteini DNA ratio, an 
estimate of cell size, was significantly depressed when protein was 
omitted from the diet (g protein/g DNA = 336 ± 16; 418 ± 16; 458 ± 18; 
and 464 ± 17 for rats fed 0%, 9%, 25% or 50% casein respectively). 
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The effect of consuming 0%, 9%, 25% or 50% casein diets for 10 
days on the percentage of active BCDH in muscle are shown in Figure 3A. 
Measurements were made before (postabsorptive) or 3 hours after 
(postprandial) presentation of the meal. 
food in their stomachs at sacrifice. 
All postprandial rats had 
Compared to postabsorptive 
values, consumption of the 0% or 9% casein diets had no significant 
effect on the activity state of the complex. In contrast, the activity 
state of BCDH increased markedly (-7-fold) after consumption of the 25% 
or 50% casein diets. The postabsorptive activity of BCDH was identical 
in rats fed 9% or 25% casein; however the postprandial activity was 80% 
lower in the former group. Consumption of the diet containing 50% 
casein resulted in greater than 3-fold increases in both postabsorptive 
and postprandial BCDH activities when compared to the group fed the 
normal protein diet (25% casein). The postabsorptive BCDH activity in 
rats fed 50% casein was significantly higher than the activity in the 
9% or 25% casein-fed rats. Interestingly, consumption of a protein-
-free diet resulted in significantly higher postabsorptive activities 
than observed in the 9% and 25% casein groups. 
The effects of dietary protein on total BCDH activity (an estimate 
of enzyme content) are shown in Table 1. Total BeDH activity was not 
significantly different in rats fed the 25%, 9% or 0% casein diets. In 
contrast, consumption of high levels of protein resulted in increases 
in total BCDH activity when expressed per mg DNA or per g protein 
(Table 1). Hence, the apparent amount of BCDH complex per muscle cell 
increased -35% after feeding a high protein diet for 2 weeks. 
We have recently demonstrated that infusions of leucine result in 
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activation of rat muscle BCDH (5). Therefore, plasma BCAA concentra-
tions were measured in the present study. As shown in Figure 3B, the 
concentration of plasma leucine increased in direct proportion to the 
protein content of the diet. In general, the increases in plasma 
leucine paralleled the changes in the activation state of the complex 
(r = 0.781 ; n = 62; p < 0.001). Similar relationships were observed 
between the activity state of BCDH and the plasma concentrations of 
isoleucine or valine (r = 0.783 for both; n = 62; P < 0.001). However, 
a causal relationship between these amino acids and the activity of the 
complex is unlikely as we have shown previously that infusions of equi-
molar amounts of valine or isoleucine fail to activate BCDH (5). The 
intracellular concentrations of leucine were measured in muscles of 
some rats before and after consuming the four diets (Table 2). 
Intracellular leucine concentrations were significantly correlated (r = 
0.498; n = 40; P < 0.01) with the activity of muscle BCDH. The 
intracellular concentrations of leucine increased postprandially in 
rats fed 9%, 25% or 50% casein, but not in rats fed the protein free 
diet. The postabsorpti ve intracellular leucine concentrations were 
similar among the groups fed 0%, 9% or 25% casein diets, but were 
increased in the group fed the 50% casein diet. The postprandial 
intracellular leucine concentrations were significantly higher in the 
groups fed 25% and 50% casein, than in those fed 0% casein. Meal 
consumption had no significant effect on the ratio of leucine concen-
trations between muscle and plasma in any of the diet groups. Inter-
estingly, the highest muscle/plasma ratios were observed in the group 
fed the protein-free diet. Postprandially this ratio was significantly 
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higher in the 0% casein group than in any of the groups fed protein 
containing meals. 
Acute Effects of Dietary Protein. To examine the effects of acute 
protein consumption on muscle BCDH, rats previously fed a 25% casein 
diet for 2 weeks were offered a single meal of 9%, 25%, or 50% casein. 
No differences in food intake were observed between the three groups. 
As shown in Figure 4A, consumption of the 9% casein meal had no effect 
on muscle BCDH activity 3, 6, or 12 hours after feeding. In contrast, 
consumption of the 25% and 50% casein meals resulted in 6 and I1-fold 
increases in the percentage of active complex 3 hours after presen-
tation of the meal (postabsorptive 1.6 ± 0.1% active; postprandial 9.4 
± 2.0 and 17.2 ± 3.6% active respectively). By 6 hours, the proportion 
of BCDH in the active form in rats offered the 25% casein meal returned 
towards baseline and changed little after 12 .hours. The percentage of 
active complex in rats offered the 50% casein meal decreased in a 
linear fashion between 3 and 12 hours after presentation of the meal. 
By 12 hours, BCDH activity in the high protein group was still 50% 
greater than baseline. 
The effect of consuming single meals of varying protein content on 
the plasma concentrations of leucine is illustrated in Figure 4B. A 
strong correlation (r = 0.852; n = 45; P < 0.001) was observed between 
the percentage of active BCDH and the concentration of leucine in 
plasma. Significant correlations were also observed between the acti-
vity of BCDH and the plasma concentrations of isoleucine (r = 0.854; 
n = 45; P < 0.001) and valine (r = 0.906; n = 45; p < 0.001). 
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The relationship between the percentage of active BCDH and 
circulating leucine in both the chronic and acute studies is shown in 
Figure 5. Linear regression analysis between % active complex and 
plasma leucine concentration demonstrated a significant direct corre-
lation between these values (r = 0.788. n = 107, p < 0.001). A better 
linear least squares fit was obtained by semilog transformation of the 
data (i.e. log % active complex vs. plasma leucine concentration) which 
gave a correlation coefficient of 0.848 (p < 0.001). The solid line in 
Figure 5 represents the best fit line for the semilog transformation. 
Leucine Infusion Studies. In rats fed a 9% casein diet for 10 
days, consumption of the meal resulted in an approximate doubling in 
plasma and intracellular leucine without a change in the activity of 
the complex (compare Figures 3A, 3B and Table 2). Also, the enzyme 
from rats fed a protein-free diet required a longer period of incuba-
tion to attain maximal activity (Figure 2). To study the apparent 
refractoriness of the enzyme from low protein-fed rats to activation, 
rats previously fed adequate (25% casein) or low (9% casein) protein 
diets for approximately 2 weeks were infused with varying doses of 
leucine (Figure 6). BCDH activity was closely correlated with the dose 
of leucine infused (r = 0.92 for each diet group, p < 0.001) and 
leucine infusions at doses of 25 J..lmol/lOOg body weight or greater 
resulted in activation of muscle BCDH in both diet groups (Figure 6A). 
However, the leucine-mediated activation of muscle BCDH from low 
protein-fed rats was less than that observed in rats fed adequate 
amounts of protein (p < o. 001), by comparison of the slopes of the 
regression lines for leucine dose vs. BCDH activity). Plasma BCAA 
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concentrations were essentially identical in the two groups (Figure 6B 
and C). 
Discussion 
The body pools of most amino acids are enlarged in animals immedi-
ately after they have consumed a high protein diet (106,145). Contin-
ued consumption of amino acids in quantities greatly in excess of 
requirements would result in death if no homeostatic controls were 
present. The relatively high Kro's of amino acid-degrading enzymes 
enable the rate of oxidation of surplus amino acids to increase 
initially as the result of increased substrate concentrations (106). 
However, if a high influx of amino acids continues, the organism 
synthesizes more of many of the rate-limiting amino acid-degrading 
enzymes found in liver. Prominent among these inductions are: serine-
threonine dehydratase; histidase; tryptophan pyrrolase; tyrosine-
a-ketoglutarate aminotransferase; glutamate-oxaloacetate and glutarnate-
-pyruvate aminotransferases; and all of the urea cycle enzymes-
(reviewed in 63,66,79,106). Hence, excesses of amino acids are 
catabolized and in the process t essential precursors for gluconeoge-
nesis (i.e. pyruvate, tricarboxylic acid cycle intermediates) are 
formed. A similar control mechanism for BCAA is believed to be absent 
(106). Reports of BCAA aminotransferase induction by diet are incon-
sistent and the observed effects are relatively small compared to other 
amino acid-degrading enzymes (77,106). Yet, BCAA oxidation in vivo is 
increased markedly after high protein feeding (109,129a,182a). In rats 
adapted to a high protein diet J the protein content of the body does 
not increase, and BeAA excretion in urine and feces is negligible (79). 
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Based on these considerations, Harper et a1. (17, 77) calculated that 
when rats are switched from a 20% to 50% protein diet, 12,000 ~mol BCAA 
are available for degradation, while the increase of BCAA in bodily 
fluids is only -100 ~mol. Hence, extensive oxidation of BCAA must be 
occurring. In the present study, a small increase in total BCDH 
activity/mg DNA was observed in rats after feeding a high protein diet 
for two weeks. This may represent stimulation of enzyme synthesis 
and/or decreased degradation of the complex. However, the major effect 
of protein intake was exerted at the level of enzyme activation. 
BCDH activity is thought to be the major regulator of BCAA oxida-
tion in vivo (117). As liver BCDH is fully active in normally-fed rats 
(69,77,81,185), activation of extrahepatic BCDH would be expected to 
result in enhanced oxidation of BCAA in vivo. In the present study, 
skeletal muscle BCDH was only 1-2% active during the postabsorptive 
period in rats fed 25% casein (Figures 3A and 4A). Increasing the 
casein content of the diet from 25% to 50% for 10 days resulted in a 
greater than 3-fold increase in the percentage of active muscle BCDH 
measured either before or 3 hours after feeding (Figure 3A). Further-
more, compared to postabsorptive values, consumption of the 25% or 50% 
casein diet resulted in a greater than 7-fold activation of muscle 
BCDH. The proportion of BCDH in the active form rose from 2% in 
postabsorptive rats fed adequate amounts of protein to greater than 40% 
in rats 3 hours after consuming a high protein diet. That a single 
normal or high protein meal could also activate muscle BCDH is shown in 
Figure 4A; the duration and magnitude of activation was proportional to 
the protein content of the diet. 
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Considering all available data, we observed a strong correlation 
between circulating leucine and the activity of muscle BCDH. Inspec-
tion of the points in Figure 5 suggests that a threshold phenomenon 
may obtain at leucine concentrations less than 0.2 roM with a fairly 
steep slope for activation of muscle BCDH at leucine concentrations 
greater than 0.2 mM. At low circulating leucine concentrations, liver 
would, therefore, assume greater importance in BCAA homeostasis but as 
circulating BCAA and muscle BCDH activity increase the latter may 
become the predominant tissue in BCAA metabolism. The correlation 
between plasma leucine and muscle BCDH activity (5) is most simply 
explained by inhibition of BCDH kinase by a-ketoisocaproate (150), the 
transamination product of leucine. In studies of rats it was found 
that the concentrations of BeKA in muscle paralleled those of the BCAA 
in rats fed low, normal or high protein diets (91) and plasma a-KIe was 
found to increase in man after a protein meal (165). It is clear 
however that this simple explanation for the relationship between 
muscle BCDH and plasma leucine is inadequate. Despite similar circula-
ting leucine concentrations, muscle BCDH in rats fed a 9% protein diet 
activated less than BCDH from rats fed a 25% protein diet (Figure 6). 
Furthermore, meal-induced activation of BCDH was greater than that 
observed after leucine infusions achieving similar plasma leucine 
concentrations (compare Fig. 4 and 6). The two studies are not 
directly comparable however because the duration of hyperleucinemia 
before sacrifice was much longer in the former experiments. It is also 
noteworthy that the postprandial activation of BCDH by a high protein 
meal (40% active) was -2.5X greater in rats maintained on a high 
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protein diet than in those maintained on a normal diet although plasma 
leucine was only 50% higher in the former group after consumption of 
the protein meal (compare Fig. 3 and 4). It seems unlikely that rneal-
induced insulin release played a role in the postprandial activation of 
BCDH, as treating postabsor~tive rats with large doses of insulin and 
glucose did not activate the complex in muscle (15). Furthermore, in 
perfused hindlimbs of postabsorptive rats, insulin added to the 
perfusate decreased flux through BCDH (93). 
Despite a marked activation of muscle BCDH in rats fed a high 
protein diet, plasma and tissue concentrations of BCAA remained 
elevated (Figures 3,4; Table 2). The BCAA aminotransferase reaction is 
readily reversible and indeed 80-90% of leucine transaminated to 
a-ketoisocaproate is reaminated to leucine in humans in vivo (117). 
High levels of tissue glutamat~ in animals fed high protein diets would 
favor maintenance of elevated BCAA by restraining their transamination 
and favoring reamination of BeKA (77,93). The physiological advantage 
of maintaining enlarged BCAA pools during high protein feeding is 
unknown. Elevated BCAA concentrations in blood could act as a protec-
tive buffer, competing with other large neutral amino acids (e.g. 
tyrosine, tryptophan and phenylalanine) for transport across the 
blood-brain barrier (135,145), thus preventing increased synthesis of 
certain neurotransmitters (61,197). The toxic effects of elevated 
brain aromatic amino acids are well documented (11). SCAA have been 
used clinically to reduce the levels of brain aromatic amino acids in 
hepatic encephalopathy (189) and phenylketonuria (12). 
Consumption of protein deficient diets results in inactivation of 
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liver BCDH (69,81,137,138). Recently, increased BCDH kinase activity 
was reported in livers and hearts of rats fed a protein-free diet (55). 
The decrease in the percentage of active complex in livers of rats fed 
low protein diets presumably represents a mechanism by which essential 
BCAA are conserved during periods of protein depletion. Indeed, BeAA 
oxidation is severely depressed in man and rat after low protein 
feeding (109,121,129,153,171). In the present study, switching from an 
adequate to a low protein diet for 10 days had no significant effect on 
muscle BCDH activity in the postabsorptive state (Figure 3A). This is 
not surprising as most of the complex was already in an inactive form 
in postabsorptlve rats fed the adequate protein diet (i.e. 2% active). 
However, the following observations were of interest: 1) muscle BCDH 
from rats fed protein-free or low protein diets required a longer 
period of preincubation with Mg2+ to attain maximal activity than BCDH 
from rats fed adequate protein diets (Figure 2) and 2) plasma leucine 
concentrations increased approximately 2-fold after consumption of the 
low protein diet, but muscle BCDH activity remained unchanged (Figure 
3) .. To further invest igate these di fferences , varying amounts of 
leucine were infused into rats fed adequate or low protein diets. 
Despite similar circulating leucine concentrations, the complex from 
rats fed the low protein diet was less responsive to leucine activation 
than the enzyme isolated from rats given adequate amounts of protein 
(Figure 6). The refractoriness of muscle BCDH to activation in rats 
fed low protein diets may be of physiological significance. An 
activation-resistant complex in muscle from low protein-fed rats, along 
with an inactivated complex in liver, would ensure efficient conserva-
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tion of BeAA during periods of protein depletion. The mechanism of 
this resistance is not clear; in view of the findings of Espinal et al. 
(55) increased skeletal muscle BCDH kinase activity in response to 
protein depletion is an attractive hypothesis. 
We have no explanation for the increased basal BCDH activity 
observed in postabsorptive rats maintained on the protein-free diet 
(Fig. 3). These animals were in a protein-catabolic state but intra-
cellular leucine concentrations were not significantly different from 
the values in the 9% and 25% casein groups (Table 2). The ap-
parent increase in the muscle/plasma leucine ratio in this group (Table 
2) may be a reflection of accelerated net degradation of muscle 
protein. a-Ketoisocaproate is compartmentalized in muscle cells (94); 
whether intramitochondrial a-ketoisocaproate is increased in muscles of 
protein-starved rats or if other mechanisms lead to the relatively 
modest activation of the complex in the postabsorptive state is not 
known. 
Our studies were carried out in rats trained to consume their 
daily caloric requirements during a relatively short period of time. 
Since rats are predominantly nocturnal "nibblers" rather than "meal-
eaters", the postprandial activation of BCDH may be less marked when 
normal feeding patterns are maintained. In rats fed a normal diet ad 
libitum the plasma leucine concentration cycles between a nadir of 170 
~M at 6 PM and a peak of 275 ~M at 6 AM (60). Man however is a meal 
eater; following a protein meal most of the absorbed amino acids 
(except for the BCAA) are taken up by the liver, while a large fraction 
of BCAA is taken up by muscle (188). Since BCAA concentrations in 
muscle generally parallel plasma concentrations (reviewed in 77) and 
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the latter increase 2-3 fold after a protein meal in man (129,165,188), 
muscle BCDH may be activated and likely contributes to the postprandial 
increase in BeAA oxidation (129) • Our studies in rats may have 
practical implications for nutritional therapy in some patients. 
Distribution or presentation of dietary protein in a manner to avoid 
large increases in circulating BCAA, or slowing the rate and extending 
the duration of amino acid infusions, may prevent or decrease activa-
tion of muscle BCDH and spare BCAA for protein synthesis. 
Our data support an active role for skeletal muscle in the 
disposal and conservation of BCAA. Muscle releases BCKA to the blood 
stream for eventual uptake and oxidation by the liver (77 J 184). In 
addition, during periods of protein surfeit, the capacity to oxidize 
BCAA carbon increases markedly in skeletal muscle, while during periods 
of protein inadequacy, skeletal muscle, along with liver, adapts to 
conserve essential BCAA. 
Table 1. Effects of Dietary Protein on Total Muscle BCDH Activities Expressed on a Wet Weight, 
Protein, or DNA Basis. 
Casein Body Wt Chg DNA Protein Total BCDH Activity in (nmol/min) x 
(%) (g/10 days) (~g/g) (mg/g) (g tissue)-l (mg DNA)-l (g protein)-l 
0 -41 ± 2a 537 ± 16a 174 ± 7a 64 ± 5a 120 ± lOa 368 ± 23a ,b 
9 +40 ± 4b 448 ± ISh 188 ± 12a ,b 63 ± 6a 140 ± 9a 332 ± 14a ,b 
25 +64 ± 2c 466 ± 13b 222 ± 11 b 63 ± Sa 135 ± 14a 304 ± 35a 
50 +S9 ± 2c 432 ± 16b 200 ± IOa,b 78 ± 4a 185 ± ISh 406 ± 3Sb 
Rats were trained to meal-feeding on a 25% casein diet as described in Materials and 
Methods, then changed to diets with varying casein content as shown for a period of 10 days. 
Starting weights were not different between rats fed the four diets (205 ± I g, n = 64). DNA, 
protein, and total BCDH activities expressed per gram of tissue were unaltered 3 hours after 
feeding. Therefore, postabsorptive and postprandial values for each diet group were pooled. 
Numbers represent mean ± SEM for n = 13 (0% casein), 15 (9% and 50% casein) or 21 (25% casein) 
rats/group. DNA, protein and total BCDH activities were measured as described in Materials and 
Methods. Values in vertical columns with different superscript letters are significantly 
different (p < 0.05). 
\.0 ...... 
92 
Table 2. Effects of Dietary Protein on Muscle Intracellular Leucine 
Concentrations and Intracellular MUscle/Plasma Leucine Ratios Before or 
After the Meal. 
Intracellular 
Leucine Concentration * 
(nmol/ml) Muscle/Plasma Leucine 
Casein (%) B A B A 
0 134 ± 24a 106 ± 16a* 1.61 ± 0.26a 1.64 ± 0.35a 
9' 94 ± lOa 162 ± 8a* 1.25 ± O.31 a ,b 1.02 ± 0.13b 
25 128 ± 24a 300 ± 17b* 1.00 ± 0.12b 0.95 ± O.03b 
so 244 ± 53b 371 ± 52b* 1.02 ± 0.14b 0.70 ± 0.07b 
Casein diets were fed for 10 days and values listed are from 
before (B) or three hours after (A) presentation of the meal. Plasma 
and muscle leucine concentrations were determined as described in 
Materials and Methods. Values are means ± SEM for 5 rats/group. Values 
in vertical columns with different superscript letters are signifi-
cantly different (p < 0.05). 
* Intracellular concentrations of leucine were calculated according to 
the following formula: 
intracellular [leu] = (nmol leu/g muscle) - (0.2)(nmol leu/ml plasma) 
0.6 
* p < 0.05 compared to before meal values. 
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Figure 1. Linearity of Basal Muscle BCDH From Rats Fed Differing 
Levels of Protein. 
Rats were meal-fed diets containing 0, 25 or 5070 casein for 
approximately 2 weeks. Muscles were frozen in situ after 3 hours of 
feeding. Basal BCDH activity was measured for 1, 2 or 5 min using 150 
~l of enzyme extract, as described in Materials and Methods. Values 
represent mean ± SEM for enzyme activities from 4 rats per diet group. 
Identical values were obtained when 100 ~l of enzyme extract was used 
(data not shown). 
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Figure 2. Effect of Preincubation Time on The Activation of MUscle 
BCDH Isolated From Rats Fed Differing Levels of Protein. 
Rats were treated as described in Figure 1. Total BCDH activity 
was measured as described in Materials and Methods. Enzyme activities 
were measured after 20, 40, 60 or 80 minutes preincubation with 15 mM 
Mg+. Values represent mean ± SEM for enzyme activities from 3-4 rats 
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:Figure 3. Chronic Effects of Dietary Protein on the Percentage of 
Active MUscle BCDB and the Plasma Concentration of Leucine. 
Rats were meal-fed diets containing 0, 9, 25 or 50% casein for 10 
days. On the tenth day, rats were killed before (open bars) or 3 hours 
after (hatched bars) presentation of che meal. All postprandial rats 
had food in their stomachs at the time of sacrifice. Muscle BCDH 
activity was measured as described in Materials and Methods and the 
percent active complex (Panel A) computed as basal (in vivo) activity 
divided by total (fully-active) activity x 100. Total BCDH activities 
for each diet group are given in Table 1. Plasma leucine concentra-
tions (Panel B) were measured as described in Materials and Methods. 
Before meal values represent means ± SEM for n = 5 (0%, 9%, 50% casein) 
or 11 (25% casein) rats per group. After meal values represent means ± 
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llaura 4. Effects of Sinale Meals of Varying Protein Content on Muscle 
BCDB and the Plasma Concentration of Leucine. 
Rats were meal-fed a diet containing adequate amounts of protein 
(25% casein) for approximately 2 weeks, then killed before or 3, 6 or 
12 hours after presentation of meals containing 9%, 25% or 50% casein. 
Food was wi thdrawn 3 hours after presentation. All rats had food in 
their stomachs after 3 hours and no difference in food intake was 
observed (14 ± 1 grams consumed, n = 15 rats). Muscle BCDH activity 
(Panel A) and plasma leucine concentrations (Panel B) were measured as 
described in Materials and Methods. Values represent mean ± SEM for 
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Figure 5. Relationship of Skeletal Muscle BCDH Activity to the 
Concentration of Circulating Leucine. 
Values from the chronic (closed circles) and acute (open circles) 
protein studies were taken from Figures 3 and 4 respectively. The 
curve shown was calculated from the best linear least squares fit which 
was obtained after semi log transformation of the data (i. e. log % 
active complex vs plasma leucine) and yielded a linear correlation 
coefficient of 0.848 (p < 0.001; n = 107). Analysis of the non-trans-
formed data by linear regression yielded a correlation coefficient of 
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Figure 6. Leucine-Mediated Activation of Muscle BCDB Isolated From 
Rats Fed Adequate or Low Protein Diets. 
Rats were fed a 9 or 25% casein diet ad libitum for approximately 
2 weeks. After an overnight fast, rats were infused with saline or 10, 
25, 50 or 100 ~mol L-leucine per 100 g body weight via the tail vein. 
Rats were killed 15 minutes after infusion and the percentage of BCDH 
in the active state (Panel A) and plasma BCAA concentrations (Panels B 
and C) were measured as described in Materials and Methods. Values 
represent means ± SEM for 4 rats per group. BCDH activation in 
response to leucine was significantly depressed in rats fed the low 
protein diet (p < 0.01 after injection of 50 or 100 ~mol leucine/IOO gj 
p < o. 001 by comparison of the slopes of the regression lines for 
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Chapter V 
Effects of Diabetes and Starvation on Skeletal MUscle 
Branched-Chain a-Keto Acid Dehydrogenase Activity 
105 
SUJIIIDary 
Branched-chain a-keto acid dehydrogenase (BCDH)* is rate limiting 
for branched-chain amino acid (BCAA) catabolism in muscle and is 
regulated by phosphorylation-dephosphorylation. Circulating BCAA 
increase with insulinopenic diabetes and starvation despite accelerated 
oxidation. 
muscles. 
The activation state of BCDH was studied in rat hindlimb 
Diabetes (streptozotocin-induced and spontaneous BB/W) 
increased circulating BCAA 4-5 -fold and BCDH activity ·-3-fold. 
Insulin treatment caused near normalization of circulating BCAA without 
correcting BCDH activity. Adrenalectomy of diabetics decreased 
(without normalizing) circulating BCAA and BCDH activation. Starvation 
caused mild, progressive increases in circulating BCAA and significant 
activation of BCDH only after 4 days. Leucine infusion activated BCDH 
in control, fed rats; the response was blunted by diabetes and to a 
lesser degree by starvation. In isolated perfused hindlimbs (control 
and diabetic) insulin did not affect BCDH significantly; perfusion with 
leucine activated BCDH, this response was blunted in diabetics. 
Activation of muscle BCDH may contribute to increased BCAA catabolism 
in diabetes; blunted activation response to hyperleucinemia may spare 
BCAA and contribute to their persistent elevation in plasma. 
Introduction 
Starvation and diabetes mellitus are conditions associated with 
elevated circulating concentrations and increased metabolism of the 
essential branched-chain amino acids (BCAA), leucine, valine and 
'* Abbreviation used in this chapter are: BCAA, branched-chain 
amino acids; BCDH, branched-chain a-keto acid dehydrogenase. 
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isoleucine, in humans (154,178,179) and animal models (6,139,182). 
BCAA are unique among the essential amino acids as they are catabolized 
extensively by extrahepatic tissues (77); skeletal muscle is thought to 
playa major role in their disposal (5,67,77). Skeletal muscles from 
diabetic or starved rats incubated in vi tro (6,27,139) and perfused 
hindlimbs from starved rats exhibit accelerated oxidation of BCAA (93). 
Insulin addition had no effect on the oxidation of medium leucine by 
diaphragms from diabetic (27) or normal (115) rats incubated in vitro 
but in perfused hindlimbs insulin caused an inunediate increase in 
leucine oxidation in preparations from starved rats but not from fed 
rats (93). 
In humans with type I diabetes mellitus the total body oxidation 
of BCAA is markedly increased after insulin withdrawal (154,179). Yet, 
BCAA uptake by tissues of the leg (predominantly muscle) after a 
protein meal was greatly diminished in insulinopenic patients (188). 
In normal humans BCAA uptake by the leg was found to be independent of 
the insulin concentration (53); but in experiments using tracer 
techniques insulin decreased leucine oxidation and turnover in a 
dose-dependent manner in normal humans (175). Similarly, insulin 
decreased leucine release by liver and muscle in normal dogs (1). 
The activity of branched-chain a-keto acid dehydrogenase complex 
(BCDH), which catalyzes the irreversible oxidative decarboxylation of 
the three branched-chain a-keto acids produced by reversible trans-
amination of the BCAA, is considered rate-limiting for BCAA catabolism 
by skeletal muscle (77,131). BCDH, is an intrarnitochondrial multi-
enzyme complex analogous to other a-keto acid dehydrogenase complexes 
(e.g. pyruvate). 
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The activity of BCDH is regulated by a reversible 
phosphorylation (inactive)-dephosphorylation (active) cycle, catalyzed 
by specific BCDH kinase (77,142,150) and BCDH phosphatase (152) 
enzymes. In the postabsorptive state, BCDH is nearly totally inactive 
in skeletal muscle of fed rats (Chapter 4,5,15,77,150,184), but muscle 
BCDH activity increases rapidly following a protein meal (Chapter 4) or 
i.v. infusion of small doses of leucine (5). The activity of muscle 
BCDH also increases after administration of large doses of isoleucine 
but valine administration had no effect; this presumably reflects the 
relative efficacy of the ketoanalogues of the BCAA at inhibiting BCDH 
kinase (ketoleucine > ketoisoleucine » ketovaline; refs. 142,150). 
The activity of BCDH in rat kidney, and liver decreased while the 
heart activity was unaffected by alloxan diabetes (151), but BCDH 
activity decreased in each of these tissues after 2 days of starvation 
(151). BCDH acti vi ty in rat muscle homogenates was unaffected by 3 
days of starvation (184). Considering that under physiological condi-
tions muscle BCDH is activated in response to increases in circulating 
BCAA (Chapter 4,5), increased muscle BCDH activity would be expected in 
diabetes or starvation. Using diaphragm muscles incubated in vitro no 
evidence for this could be obtained (6). As mentioned above, the role 
of insulin in regulating BCAA oxidation in muscle is not clear (1,27, 
93,151); there is considerable evidence however that insulin retards 
whole body BCAA catabolism (1,65). Whether this is due solely to the 
protein anabolic effects of insulin (i.e. stimulation of protein 
synthesis and inhibition of protein degradation) decreasing BCAA flux 
through BCDH, or BCDH activity is also affected remains unresolved. In 
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the present study a recently developed method for determining the 
activity state of skeletal muscle BCDH in vivo was used to assess 
changes in the activity of this enzyme complex during insulinopenic 
diabetes and starvation t and to determine whether the activity of BCDH 
is subject to acute regulation by insulin. 
Materials and Methods. 
Animals and Animal Treatments. Male Wistar rats t strain WI(BR)t 
were obtained from Charles River Laboratories t Wilmington t MA. In some 
studies a spontaneously diabetic strain of Wistar rats (BB/W) was used 
(116); these were kindly supplied by Dr. Arthur Like of the University 
of Massachusetts t Worcester, MA. Rats were housed in an animal 
facility maintained at 25°C with a 12 hour light-12 hour dark cycle 
(light from 0600 - 1800). Animals were maintained on Wayne Rodent Blox 
(Continental Grain t Chicago, 1L) chow (2470 protein) and water, both 
supplied ad libitum. 
Diabetes mellitus was induced by a single intraperitoneal injection 
of streptozotocin (120 mg/kg body weight in 0.05 M sodium citrate, pH 
4.5). Rats were tested for glycosuria with Tes-Tape (Eli Lilly & Co., 
Indianapolis t IN) the day following streptozotocin injection. All rats 
having greater than 2+ glycosuria were started on a regimen of 2 units 
Humulin R insulin + 2 units Humulin N insulin (Lilly) injected subcu-
taneously each morning and evening. Insulin therapy was maintained for 
at least 60 hours then was discontinued 72 hours prior to sacrifice 
when untreated diabetic animals were studied; these animals were 
presumed to have been insulinopenic for about 60 hours. Insulin-
treated animals were continued on the above insulin therapy but the 
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morning of the experiment they received only 2 units Humulin R insulin 
2-3 hours prior to sacrifice. 
BB/W rats were checked daily for glycosuria; after glycosuria 
developed plasma glucose was determined on blood obtained from the tail 
veins. Diabetic BB/W rats were treated with single daily injections of 
1.2-2 units of protamine zinc insulin (Lilly), with the dose being 
adjusted to maintain glycosuria less than 3+ by Tes-tape and no 
ketonuria as determined with Ketostix (Ames Division, Miles Labora-
tories, Elkhart, IN). When untreated BB/W diabetic rats were studied 
insulin therapy was discontinued 72 hours prior to sacrifice. 
Adrenalectomy of diabetic rats was performed on the day of their 
last insulin injection under ether anesthesia either by bilateral 
subcostal approaches or a dorsal approach. Adrenalectomized animals 
were supplied 0.9% (w/v) NaC! to drink ad libitum, and killed on the 
third day after operation. Rats weighed between 150 and 220 g at the 
time of sacrifice, except for BB/W rats and the rats used for hindlimb 
perfusions which typically weighed 280 to 350 g. 
In some experiments central venous catheters were placed, under 
light ether anesthesia, in an internal jugular vein of rats as previ-
ously described (6,76). Catheters were placed -20 hrs prior to leucine 
infusions. Leucine (0.1 M in 0.9% NaCl, 250 ~mol/kg b.w.) or an equal 
volume of saline was infused by jugular catheter or by tail vein 
injection while rats were under light methoxyflurane (Pitman-Moore, 
Washington Crossing, NJ) anesthesia. Muscle and blood samples were 
obtained as described below 15 min after leucine or saline infusion. 
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BCDH Assay. The method to assess BCDH activity in vivo was 
described in detail previously (5,15). Briefly, rats were anesthetized 
with methoxyflurane and muscle samples frozen in situ at liquid 
nitrogen temperature. BCDH complex was extracted from powdered frozen 
muscle in a detergent solution containing protease, phosphatase and 
kinase inhibitors. In vivo BCDH activity was estimated using the 
freshly prepared complex and total (dephosphorylated) activity esti-
mated after incubation at 37°C with 15 roM Mg2+; % active complex was 
calculated from the ratio of in vivo to total BCDH activities in the 
same muscle sample. Enzyme acti vi ty was estimated as 14C02 release 
from 0.1 mM a-keto[1- 14C]isocaproate, as described previously (5,15). 
Preliminary experiment established that total BCDH activity in muscle 
extracts prepared from diabetic rats reached a maximum after 60 min 
incubation with Mg2+, as previously found in normal rats (5). 
Hindlimb Perfusions. Isolated rat hindlimb preparations were 
prepared under pentobarbital anaesthesia and perfused essentially as 
described by Jefferson (98). The perfusion medium consisted of Krebs-
Henseleit buffer containing aged, rejuvenated human erythrocytes (12 g 
hemoglobin per 100 m!), 4% (w/v) bovine serum albumin, and 5.5 mM 
D-glucose; insulin when present was added at a concentration of 10 mU I 
ml. During preparation an additional tie was loosely placed around the 
internal iliac vessels on one side. After 15 min of perfusion one limb 
was skinned, the gastrocnemius freeze-clamped in situ and removed. then 
the flow rate was reduced, the internal iliac tie knotted and the limb 
isolated by an umbilical tape tie at the level of the hip. Leucine 
infusion was started via a second pump connected piggy-back to the main 
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perfusion line set to produce a final concentration of 1 mM in the 
perfusate. After 15 min additional perfusion the remaining gastroc-
nemius was frozen in situ and removed. 
Amino acid and glucose determinations. Blood samples were col-
lected by cardiac puncture using a heparin-treated syringe and plasma 
deproteinized by addition of 0.1 volume of 50% (w/v) sulfosalicylic 
acid. Amino acids were extracted from frozen powdered muscle samples 
by addition of -4 ml/g ice-cold 6% sulfosalicylic acid. Particulate 
material in all preparations was removed by centrifugation and the 
samples stored at -20oe or below until amino acid concentrations were 
determined by reversed-phase high performance liquid chromatography of 
the 2--phthalaldehyde derivatives with fluorescent detection as descri-
bed previously (6). Plasma glucose concentrations were determined by a 
glucose oxidase method using a Beckman Glucose Analyzer 2 (Beckman 
Instruments Inc .• Fullerton. CA). Reagents were obtained from sources 
described previously (5,6,15) and were reagent grade or higher quality. 
Statistics. All values are presented as mean ± SEM. Comparisons 
were conducted using either Student 1st test or analysis of variance 
followed by a multiple comparison test (Peritz F test; 80), where 
appropriate. Analysis of values expressed in per cent was conducted 
after angular transformation, to assure normal distribution (173). 
Results 
Muscle BCDH activity in stretozotocin-diabetic rats. The in vivo 
activity of muscle BCDH in rats rendered diabetic with streptozotocin 
was about 2.S-fold greater than in normal, fed rats whether expressed 
as actual activity or % active complex (Table 1, without leucine 
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infusion). Plasma leucine was increased more than 5 fold by diabetes, 
similar increases were observed in plasma valine and isoleucine (data 
not shown). Insulin treatment of diabetic rats markedly decreased 
plasma glucose concentrations (from 512 ± 37 mg/dl in diabetic rats to 
70 ± 13 mg/dl in insulin treated diabetic rats compared with 171 ± 8 in 
normal rats) and decreased plasma leucine concentrations to normal 
values (Table 1). BCDH activity remained about 2-fold greater in 
insulin-treated diabetic rats compared to normal rats; BCDH activity in 
insulin-treated diabetic rats was greater than in normals, while the % 
active complex in insulin-treated diabetics was between the values for 
normals and diabetics and not different from ei ther. Total BCDH 
activities were the same in control, diabetic and insulin-treated rats. 
Muscle BCDH activity in spontaneously diabetic rats. Considering 
the possibility that streptozotocin could have a direct effect on BCDH 
or one of its regulatory enzymes, causing activation of BCDH which 
could not be reversed wi th insulin therapy, the acti vi ty of BCDH was 
investigated in a spontaneously diabetic strain of rats. In the BB/W 
diabetic rat BCDH activity was increased more than 3-fold over the 
activity in non-diabetic litter-mate rats (Table 2). Insulin therapy 
did not return BCDH activity to the low levels present in non-diabetic 
BB/W rats; in vivo BCDH activity in insulin-treated diabetics was not 
different from activities in either diabetic or non-diabetic rats, 
while the % active complex in insulin-treated diabetics was different 
from non-diabetic values only. In BB/W diabetic rats total BCDH 
activity tended to be lower than in non-diabetic and insulin-treated 
diabetic rats but this effect was not significant (Table 2). 
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As in the streptozotocin-diabetic rats plasma BCAA were dramatic-
ally elevated in the BB/W diabetic rats compared to the non-diabetic 
controls (Table 3). Insulin therapy restored the plasma concentrations 
of valine and isoleucine to normal. The plasma leucine concentration 
in insulin-treated BB/W diabetic rats was much lower than in the 
diabetic rats but remained about 30% greater than in the non-diabetic 
rats. The calculated intracellular concentrations of BCAA in muscles 
of non-diabetic rats were lower than the plasma concentrations, while 
in the BB/W diabetic rats the calculated intracellular BeAA were not 
significantly different from the plasma concentrations. Insulin 
therapy decreased intramuscular BCAA concentrations to values that were 
not different from the values in the non-diabetic rats. 
Muscle BCDH activity in adrenalectomized streptozotocin-diabetic 
rats. Glucocorticoid administration was reported to activate muscle 
BCDH (15) suggesting that endogenous corticosterone might contribute to 
the activation of BCDH in diabetes; this possibility was investigated 
in adrenalectomized, streptozotocin-diabetic rats (Table 4). Total 
BcnH activity was unaffected by adrenalectomy. In vivo BCDH activity 
in diabetic rats was reduced by adrenalectomy but remained greater than 
in normal, fed rats. Similarly, plasma leucine in diabetic rats was 
markedly reduced by adrenalectomy but remained greater than in the 
control rats. 
Effect of leucine infusion on muscle BCDH activity in streptozo-
tocin-diabetic rats. In previous studies muscle BCDH was activated by 
moderate increases in circulating leucine concentration from dietary 
protein intake (Chapter 4) or intravenous administration (Chapter 4,5). 
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In view of the marked elevations in circulating and intracellular BCAA 
in diabetic rats a greater increase in muscle BCDH activity than was 
observed might be expected. This suggests that diabetes renders muscle 
BCDH refractory to activation by increased leucine. Therefore, a bolus 
of leucine (250 ~mol/kg) was administered i.v. and BCDH activity 
determined in muscle samples taken 15 minutes later (Table 1). In 
normal, fed rats leucine infusion increased BCDH activity 4-foldj 
plasma leucine increased about 50% from 151 ~M to 234 ~M. In strepto-
zotocin-diabetic rats leucine infusion increased BCDH activity and 
plasma leucine by about 50% but neither increase was significantj BCDH 
activity increased only about 20% when expressed as % active complex. 
Muscle BCDH activity increased greater than 2.S-fold in insulin-treated 
streptozotocin-diabetics after leucine infusion and was indistinguish-
able from the activity observed in normal rats after leucine infusion. 
Plasma leucine increased from 164 J..1M to 219 J..IM in insulin-treated 
diabetic rats after leucine infusion which was similar to the increase 
in normal rats. 
Muscle BCDH activity in starved rats. BCDH activity increased 
slightly after one day of starvation, significant only when comparing % 
active complex. BCDH activity then was constant until the fourth day 
of starvation when it increased abruptly (Table 5). Plasma leucine 
increased slowly over the time course of starvation and was signifi-
cantly different from the value in the fed rats on the fourth day of 
starvation (Table 5); a significant positive correlation was observed 
between plasma BCAA and duration of starvation from 0 to 4 days (r = 
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0.48, 0.56, 0.56 for valine, isoleucine and leucine, respectively; n = 
32; P < 0.01). 
To assure that measurements of total BCDH activity in these studies 
were not biased by different rates of BCDH activation in vitro as 
reported for liver BCDH in rats fed a protein-deficient diet (138) and 
for muscle BCDH in rats fed a low protein diet (Chapter 4), the time 
course of activation of BCDH in vitro in the presence of Mg2+ was 
determined (Figure 1). No apparent differences in the rate of activa-
tion or the total activity attained were observed between fed rats and 
rats fasted 1 to 4 days; maximum BCDH values were attained at 60 min 
and all further determinations used 60 min incubations for determi-
nation of total BCDH activity. In the small group of animals shown in 
Figure 1, total BCDH activity per g muscle increased with the duration 
of starvation; but when larger numbers of animals were analyzed the 
trend toward increased total BCDH activity per g muscle remained but 
was not significant (Table 5). 
The response of BCDH to i.v. infusion of leucine was determined in 
fed rats and after 2 or 4 days of starvat ion. 
increased after leucine infusion, regardless 
Muscle BCDH activity 
of the duration of 
starvation. The BCDH activity after 4 days of starvation was similar 
to that in fed rats after leucine infusion and plasma leucine concen-
trations were similar in these two groups. The BCDH activity attained 
after leucine infusion was indistinguishable in the fed and starved 
rats but progressively greater plasma leucine concentrations were found 
in the rats starved for 2 or 4 days (Table 5). 
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Effect of insulin and leucine on perfused hindlimbs of normal and 
streptozotocin-diabetic rats. The acute effects of insulin and leucine 
on the activity of BCDH in muscle were investigated in isolated, 
perfused hindlimbs of normal and streptozotocin diabetic rats (Table 
6). Addition of insulin to the perfusate resulted in slightly higher 
BCDH activities both in the absence and presence of leucine in hind-
limbs from control and diabetic rats, but the insulin effect was not 
significant in any of the groups (Table 6). When BCDH activities in 
all hindlimbs from diabetic rats were compared to all hindlimbs from 
normal rats, in vivo BCDH activity in diabetic hindlimbs was doubled 
(p < 0.01); the effect of diabetes was not significant when values for 
% active complex were compared, presumably due to differences in the 
total BCDH activities. Addition of leucine to the perfusate resulted 
in activation of BCDH in hindlimbs from both control and diabetic rats; 
no additional effect of insulin was observed. After leucine infusion, 
BCDH activity in hindlimbs from diabetic rats was less than in hind-
limbs from normal rats; the effect was significant only when values for 
% active complex for all hindlimbs receiving leucine were compared 
(Table 6). In this group of experiments total BCDH acti vi ty per g 
muscle was greater in muscles from diabetic rats than in those from 
normal rats; there was no effect of insulin or leucine on total 
activity. 
Discussion 
The present studies establish that muscle BCDH is activated in 
diabetes as would be anticipated in view of the marked increases in 
BCAA concentrations in plasma and intracellularly. The degree of BCDH 
117 
activation observed in diabetic muscles was less than previously 
observed in normal rats with similar increases in plasma leucine from 
dietary protein or leucine infusion. For example, rats maintained on a 
50% protein diet had postprandial plasma leucine concentrations greater 
than 600 ~M and muscle BCDH greater than 40% active (Chapter 4) and in 
fed rats maintained on a 24% protein diet infusion of 250 ~mol leucine 
per kg body weight increased plasma leucine to 200 - 230 ~M 15 min 
post infusion, with BCDH 7-10% active (Tables 1,5; ref. 5). Further-
more, muscle BCDH in diabetic rats did not activate after infusion of a 
leucine dose which clearly activated BCDH in normal and insulin-treated 
diabetic rats (Table 1), and BCDH in perfused hindlimbs of diabetic 
rats activated less than in controls when leucine was added to the 
perfusate (Table 6). The latter observation suggests that decreased 
activation of muscle BCDH by leucine in diabetes is not due to altera-
tions in a hormonal response to leucine infusion, and this refracto-
riness persists for at least 30 min after the muscles are removed from 
their metabolic milieu. The activation of muscle BCDH in hindlimbs of 
diabetic rats by perfusion with a leucine concentration which did not 
activate muscle BCDH in vivo in diabetic rats (compare Tables 1 and 6) 
suggests however that the metabolic milieu in vivo is at least partly 
responsible for the blunted response to leucine. Since the isolated 
hindlimbs were perfused without added amino acids (except for leucine) 
it is unlikely that the decreased response to leucine in diabetic rats 
in vivo results solely from competition of leucine with other large 
neutral amino acids (especially valine and isoleucine) for transport 
across the plasmalemma. Competition for transport could however 
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contribute to the blunted response to leucine in vivo. Impaired 
activation of muscle BCDH by increased BCAA in diabetes may contribute 
to the decreased clearance of exogenous leucine (51) and the decreased 
BeAA uptake by legs of diabetic patients following a protein meal 
(188). 
Insulin-therapy of diabetic rats tended to decrease plasma BCAA 
toward normal values (Tables 1,3,4), but did not restore BCDH activity 
despite nearly complete normalization of plasma BCAA by insulin in one 
experiment (Table 1). Persistent activation of muscle BCDH despite 
insulin therapy was not due to a toxic effect of streptozotocin since 
similar results were obtained in spontaneously diabetic rats (Table 2). 
Increased BCDH activity in diabetic rats treated with insulin could be 
due to elevation of the intracellular leucine concentration as sug-
gested in the studies of BB/W rats (Table 3), coupled with improved 
response of muscle BCDH to increased leucine (Table 1). Plasma BCAA 
were considered poor indicators of normalization of amino acid metabo-
lism by skeletal muscle in humans with type I diabetes mellitus since 
the intramuscular BCAA (and presumably branched-chain a-keto acid) 
concentrations remained elevated despite their normalization in plasma 
(18). Furthermore, the intramitochondrial concentration of ketoleucine 
(the transamination product of leucine, which is the substrate for BCDH 
and an inhibitor of BCDH kinase) may remain elevated even after 
intracellular leucine has returned toward normal (92). Our results are 
consistent with reports in patients with type I diabetes demonstrating 
that restoration of the metabolic parameters of leucine (catabolism and 
flux as assessed by tracer techniques in vivo) to normal values was 
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difficult to achieve with conventional or with insulin pump therapy 
(154,179). Based on measurements in heart, liver and kidney, Randle 
estimated that whole body BCDH active complex decreased by 50% in 
alloxan diabetes (151). The increase in muscle BCDH activity reported 
here suggests that muscle (and perhaps brain, ref. 21) are the probable 
sites of increased BCAA oxidation in insulinopenic diabetes. 
The near normalization of plasma BCAA in diabetic-adrenalectomized 
rats highlights the important role of glucocorticoids unopposed by 
insulin in the dramatic increases in plasma BCAA observed in diabetes. 
The nature of the glucocorticoid effect on circulating BCAA is not 
clear. The predominant effect of exogenous corticosterone on skeletal 
muscle protein turnover in the rat was found to be inhibition of 
protein synthesis with a much lesser effect on protein degradation 
(130), although the effect of corticosterone on protein degradation was 
enhanced in diabetic rats (177). Protein synthesis was depressed by 
50% or more in skeletal muscles of diabetic rats after about 72 hours 
of insulinopenia and protein degradation was increased (134) but the 
role of endogenous unopposed glucocorticoids in these changes remains 
undefined. The possibility of differences in food consumption between 
the diabetic and diabetic-adrenalectomized rats was evaluated in one 
experiment. During the 24 hour period immediately prior to sacrifice 
sham-operated diabetic rats consumed significantly more food than the 
adrenalectomized group; 20.6 ± 1.6 g and 9.1 ± 2.6 g, respectively, 
wi th 6 animals per group (p < 0.01). During the preceding 24 hour 
period, (24 48 hours after operation) food intakes were similar 
between the two groups, 8.6 ± 1.9 g for adrenalectomized and 9.3 ± 1.6 
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g for sham-operated diabetic rats. At present it is not possible to 
assess the relative importance of these factors (food consumption t 
protein synthesis and protein degradation) in the contribution of 
corticosterone to BCAA elevation in the diabetic rat. It appears 
however that glucocorticoids contribute to diabetes associated hyper-
phagia. 
In starvation, muscle BCDH activity was not increased significantly 
until the fourth day (Table 5); previous studies also found no change 
in muscle BCDH acti vi ty after 3 days of starvation (184) . These 
results contrast with studies of muscles incubated in vitro and 
perfused rat hindlimbs where oxidation of leucine was increased earlier 
in starvation (6,93). Recent studies of leucine metabolism in the rat 
in vivo have established that whole body oxidation of leucine is indeed 
accelerated after three days of starvation (182). It seems unlikely 
that the small increment in muscle BCDH activity observed in rats 
starved for one to three days accounts for accelerated leucine oxida-
tion early in starvation. Accelerated oxidation of BCAA may be due to 
increased flux through BCDH resulting from increased substrate supply, 
since muscle and plasma branched-chain a-keto acids (and BCAA) were 
increased in rats starved for three days (93,182) and leucine trans-
amination was increased in diaphragm muscles after an overnight fast 
(6). 
The clearance of infused leucine is markedly decreased by three or 
four days of starvat ion in man (51). A dose-response relationship 
between leucine infused and muscle BCDH activity has been reported in 
rats (Chapter 4;5), and there was a direct correlation between plasma 
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leucine concentration and BCDH activity (Chapter 4). In the present 
studies muscle BCDH in starved rats was readily activated by leucine 
infusion, unlike muscle BCDH in diabetic rats. Comparison of the 
plasma leucine concentrations in the starved rats after leucine 
infusion (Table 5) with those in fed rats (Tables 1,5) suggest that in 
starvation the normal relationship between plasma leucine and muscle 
BCDH activity may be disturbed (i.e. BCDH in starved rats may be less 
active after leucine infusion than it would be in fed rats at similar 
plasma leucine concentrations). Blunted response of muscle BCDH to 
infused leucine was previously observed in rats fed a protein-restric-
ted diet (Chapter 4). Activation of muscle BCDH may play a greater 
role in the accelerated oxidation of BCAA in diabetes than in starva-
tion (compare Tables 1 and 2 to Table 5). Although activation of BCDH 
by increased BCAA (leucine probably being most important) apparently 
can occur in both diabetes and fasting, the response is less than 
normal and may contribute to decreased clearance of exogenous leucine 
in these states. 
The tendency toward increased total muscle BCDH activity with 
duration of starvation (Table 5) is consistent with previous studies 
which found increased total BCDH activity in the gastrocnemius after 3 
days of starvation (184). Since the BCDH values are presented on a 
tissue weight basis it seems likely that increased total activity 
represents sparing of BCDH from catabolism relative to other cellular 
constituents rather than increased synthesis of BCDH during starvation. 
Increased total BCDH activity per g muscle was also observed in 
diabetic rats (Table 6) but this was not confirmed in other experiments 
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(Tables 1,2). There is no apparent explanation for these discre-
pancies. 
We were unable to detect a significant acute effect of insulin on 
the activity of muscle BCDH or its response to increased circulating 
leucine in studies of perfused hindlimhs from normal, fed or from 
diabetic rats (Table 6). Studies of leucine fluxes reported that 
insulin rapidly stimulated leucine oxidation by perfused hindlimbs of 
rats starved for three days, but decreased oxidation by hindlimbs of 
fed rats (93). The latter effect was thought to reflect decreased flux 
through BCDH secondary to increased leucine utilization for protein 
synthesis. In a previous study, the BCDH activity of skeletal muscle 
was unaffected by administering large doses of insulin with glucose to 
normal, fed rats (15). The present studies suggest that, in fed 
diabetic or control rats, insulin is not required for activation of 
muscle BCDH by increased leucine, supporting the concept that leucine 
catabolism by skeletal muscle is relatively independent of insulin 
(53). However, as insulin concentrations wane during fasting or after 
insulin withdrawal in diabetes, and the ensuing net protein catabolism 
increases BCAA available for oxidation, the normal activation of BCDH 
by increased BCAA is blunted; this may contribute to the elevation of 
circulating BCAA observed during starvation and more markedly in 
insulinopenic diabetes. 
The mechanism of diminished muscle BCDH response to leucine in 
diabetes and starvation is unresolved. The system appears to become 
refractory to normal regulation, e.g. in incubated diaphragms of fasted 
and diabetic rats flux through BCDH is resistant to inhibition by 
123 
pyruvate, which is normally observed in controls (6). Since activity 
of BCDH is dependent on the balance of the kinase and phosphatase 
reactions alterations in the activity of these enzymes may be impor-
tant. Indeed, increased BCDH kinase activity was demonstrated in heart 
mitochondria of rats starved for two days (55). BCDH kinase is subject 
to inhibition by branched-chain a-keto acids (particularly ketoleucine 
(142), presumably accounting for the direct relationship between BCnH 
activi ty and leucine concentration; Chapter 4, ref. 5), hence alter-
ations in mitochondrial branched-chain a-keto acid transport could 
affect the relationship between leucine and BCDH activity. Recent 
reports indicate that branched-chain a-keto acid transport across the 
mi tochondrial membrane is a regulated process (92,94) and may be a 
rate-limiting step for BeM oxidation (94). The phos.phatase reaction 
appears to be regulated in a complex fashion involving an inhibitory 
protein (152) but alterations in BCDH phosphatase activity in physio-
logic or pathologic states have not been reported. Other factors which 
may be altered in muscle cells by diabetes and fasting and may modulate 
activation of BCDH directly or indirectly include: redox potential 
(27), mitochondrial pH (94), acyl-CoAs (142,150,151), and possible 
protein inhibitors and activators of the complex (131,141,150). 
Further work is required to elucidate the mechanism(s) of altered 
muscle BCDH response to leucine in diabetes and fasting. 
Legend for Table 1. 
Muscle BCDH activity and plasma leucine concentration were deter-
mined in normal, streptozotocin-diahetic and insulin-treated diabetic 
rats as described under Materials and Methods. One group of rats 
received a leucine infusion (250 ~mol/kg) through a jugular venous 
catheter as described under Materials and Methods; samples were taken 
15 min after infusion. As a control for infusion, some rats in each 
group were infused with an equal volume of saline. The results in 
saline-infused and non-infused rats were not significantly different 
therefore values for all rats not receiving leucine were combined. 
Total BCDH activities were not significantly different between groups 
or treatments (40 ± 2 nmol / min / g muscle, n = 43). a p < 0.005 
compared to control; b p < 0.025 compared to control; c p < 0.025 
compared to no leucine infusion; d p < 0.005 compared to diabetic; 
e p < 0.05 compared to no leucine infusion. 
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Table 1. Effect of streptozocin-diabetes. insulin therapy and leucine 












0.9 ± 0.1 
2.6 ± O.3a 




2.8 ± 0.3 
7.1 ± 1.1h 
6.0 ± 1.2 
With leucine infusion 
4.1 ± O.3c 11.4 ± 2.7c 
4.1 ± 0.6 8.6 ± 1.1 




151 ± 8 
819 ± 2028 
164 ± I7d 
234 ± 13c 
1255 ± 2518 

















In vivo Total 
1.2 ± 0.2 46 ± 7 
4.1 ± O.9a 29 ± 5 
2.3 ± 0.6 38 ± 2 
% Active 
complex 
2.7 ± 0.4 
11.7 ± 3.2b 
6.6 ± 1 .. 6a 
Muscle BCDH activity was determined in control, diabetic, and 
insulin-treated diabetic BB/w rats as described under Materials and 
Methods.. Control rats were non-diabetic Ii ttermates of the diabetic 
BB/w rats. Values represent mean ± SEM from 6 animals in each group. 
a p < 0.05 compared to control value; b p < 0.005 compared to 
control value. 
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Table 3. Plasma and muscle branched-chain amino acid concentrations in 
BB/W rats. 
Amino Acid Concentration (~M) 
Leucine Valine Isoleucine 
Plasma 
Control 156 ± 14 248 ± 22 102 ± 10 
Diabetic 648 ± lOla 886 ± 141 a 378 ± 51 a 
Insulin-
treated 204 ± I1 b ,c 250 ± 14c 120 ± Be 
Muscle 
Control 112 ± 13d 158 ± 24d 52 ± gd 
Diabetic 660 ± 107a 837 ± 120a 371 ± 48a 
Insulin-
treated 160 ± 23c 207 ± 25c Sl± 13c ,d 
Plasma branched-chain amino acid concentrations were determined as 
described under Materials and Methods. Muscle intracellular branched-
chain amino acids were calculated from amino acid concentrations in 
muscle extracts according to the formula: 
intracellular (nmol BCAA/g muscle) - (O.2)(nmol BCAA/ml plasma) 
= 
[BCAA] 0.6 
Values represent the mean ± SEM from six animals. a p < 0.001 compared 
to control value; b p < 0.05 compared to control value; c p < 0.005 
compared to diabetic value; d p < 0.05 compared to plasma value. 
128 








1.0 ± 0 .. 1 
3.4 ± 0.5a 
% Active 
complex 
2.7 ± 0.2 
9.3 ± 1.7a 
5 .. 2 ± 0 .. 9a 
Plasma 
leucine 
153 ± 6 
719 ± 102a 





Muscle BCDH activity and plasma leucine concentration were deter-
mined in control, streptozotocin-diabetic, and adrenalectomized 
streptozotocin-diabetic rats as described under Materials and Methods. 
Normal and streptozotocin-diabetic rats were subjected to sham opera-
tion with no differences in BCDH activity or plasma leucine results 
compared to unoperated animals, the values shown for control and 
diabetic animals were pooled from sham-operated and unoperated animals. 
Total BCDH activities were not different between groups, 38 ± 1 nmol I 
min I g muscle (n = 43). a p < 0 .. 025 compared to control; b p < 0.05 
compared to diabetic. 
Legend for Table 5. 
Muscle BCDH activity and plasma leucine concentration was deter-
mined in fed rats and rats starved for 1 to 4 days as described under 
Materials and Methods. One group of rats received a leucine infusion 
(250 ~mol/kg). samples were taken 15 min after infusion. As a control 
for infusion. some rats in each group were infused with an equal volume 
of saline. The results in saline-infused rats were not different from 
those in rats which received no infusion, therefore values for all rats 
not receiving leucine were combined. a p < 0.01 compared to 4 days of 
starvation; b p < 0.05 compared to fed rats; c p < 0.05 compared to 
no leucine infusion; d p < 0.001 compared to no leucine infusion; e p 
< 0.05 compared to 4 days of starvation; f p < 0.01 plasma leucine 
concentration in each group of rats receiving leucine infusion was 
different from the leucine concentrations in the remaining two groups. 
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Without leucine infusion 
0 0.6 ± 0.18 39 ± 3 1.5 ± 0.2a 
1 1.0 ± 0.2 40 ± 2 2.5 ± 0.4b 
2 0.9 ± 0.18 40 ± 3 2.2 ± 0.3a 
3 0.9 ± 0.2a 43 ± 5 2.0 ± 0.2a 
4 2.2 ± 0.4 48 ± 4 4.6 ± 0.9 
With leucine infusion 
0 2.6 ± O.4d 37 ± 2 7.2 ± l.Od 
2 2.2 ± O.2d 40 ± 2 5.4 ± 0.6d 











145 ± Be 
158 ± lOe 
160 ± 8 
178 ± 8 
207 ± 20 
206 ± 6d ,f 
266 ± I1d,f 









Legend for Table 6. 
BCDH activity was determined in muscle samples from hindlimbs of 
normal and streptozotocin-diabetic rats perfused as described under 
Materials and Methods. Hindlimbs were perfused in the presence (+) or 
absence (-) of 10 mU/ml insulin. A first sample was taken after 15 min 
of perfusion (before leucine addition) and a second sample was taken 15 
min later after exposure to 1 mM leucine. Initial experiments showed 
no difference in BCDH activity between samples obtained after 15 or 30 
min of perfusion. Combined values (+/-) represent the pooled values 
for normal or diabetic hindlimbs perfused both in the presence and 
absence of insulin. Total BCDH activity was significantly different 
(p < 0.01) between hindlimbs of normal and diabetic rats. 25.6 ± 1.5 
(n = 22) vs. 34.9 ± 1.5 nmol/min/g muscle (n = 20), respectivelYi total 
BCDH activity was unaffected by insulin or leucine in either group. 
a p < 0.001 compared to normal rat; b p < 0.001 compared to before 
leucine addition; C p < 0.01 compared to normal rat. 
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Table 6. Effects of leucine and insulin on muscle BCDB activity in 















{nmol/ min Ig muscle} 
Before leucine addition 
0.9 ± 0.2 
1.3 ± 0.3 
1.1 ± 0.2 
1 .. 9 ± 0.4 
2.4 ± 0 .. 2 
2.2 ± O.Za 
After leucine addition 
10.8 ± 2.Sb 
12.4 ± 1.9b 
11.5 ± 1.7b 
6.4 ± o.ab 
9.3 ± 2.3b 
7.7 ± 1.3b 
% Active 
complex 
3 .. 6 ± 0.7 
4.9 ± 1.0 
4 .. 2 ± 0.6 
4.9 ± 0.6 
6 .. 5 ± 0.9 
5.7 ± 0.6 
42.6 ± lO.4b 
52.7 ± 7.0b 
43.2 ± 3.Sb 
18.6 ± 3.0b 
30.6 ± 5.6b 















Table 6. Effects of leucine and insulin on muscle BCDB activity in 















(nmoll min Ig muscle) 
Before leucine addition 
0.9 ± 0 .. 2 
1.3 ± 0.3 
1.1 ± 0.2 
1.9 ± 0.4 
2.4 ± 0.2 
2.2 ± O.2a 
After leucine addition 
10 .. 8 ± 2.Sh 
12.4 ± 1.9b 
11.5 ± 1.7b 
6.4 ± O.Sb 
9.3 ± 2.3b 
7.7 ± 1.3b 
% Active 
complex 
3.6 ± 0.7 
4.9 ± 1.0 
4.2 ± 0.6 
4.9 ± 0.6 
6.5 ± 0.9 
5.7 ± 0.6 
42.6 ± lO.4b 
52.7 ± 7.0b 
43.2 ± 3.Sb 
18.6 ± 3.0b 
30.6 ± S.6b 















Figure 1. Time course of in vitro activation of muscle BCDH from fed 
and starved rats. 
Muscle BCDH was prepared from fed rats and rats starved for 1 to 4 
days as described under Materials and Methods. BCDH was incubated at 
37°C in the presence of 15 mM Mg2+ and samples removed every 20 minutes 
for determination of BCDH activity as described in Materials and 
Methods and in references 2 and 4. Values are mean ± SEM for 3-7 rats 
per group . Curves are shown for fed animals and from the means of all 
starved animals at each point. 
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The previous chapters have presented studies of certain aspects of 
branched-chain amino acid catabolism by skeletal muscle. At this point 
some consideration will be given to how these findings relate to the 
whole body economy of the BCAA. Since synthesis de novo is not an 
option (BCAA being essential), homeostasis of the BCAA must involve 
disposal of the amino acids during times of surfei t and conservation 
during times of deficiency. In this framework it should be clear that 
regulation of branched-chain a-keto acid dehydrogenase (BCDH) is 
central to homeostatic control of the BCAA. To better understand the 
role of skeletal muscle in whole body disposal of BCAA the interactions 
between muscle and other tissues is also necessary. 
In the postabsorptive fed rat, which might be considered a neutral 
(i.e. no deficiency and no excess) condition with regard to BCAA 
homeostasis, the activity of BCDH in muscle is very low (Chapters 3-5) 
while hepatic and renal BCDH is very active (69,137,185). Under 
postabsorptive conditions it is likely that muscle is a relatively 
unimportant site for BCAA oxidation and instead is a source of circu-
lating branched-chain a-keto acids which are oxidized by liver, kidney 
and perhaps other tissues. Once protein is ingested and BCAA enter the 
systemic circulation BCDH activity in muscle increases rapidly (Chapter 
4), but except for adipose tissue (64) there is no evidence indicating 
that BCDH activity in other tissues increases postprandially. The 
importance of muscle, relative to other tissues, as a site of BCAA 
oxidation should therefore increase in the postprandial period. It 
must be noted however that circulating branched-chain a-keto acids 
increase in the postprandial period thus indicating that BCAA disposal 
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by liver may also increase during this period. As circulating BCAA 
decline during the postprandial period BCDH activity in muscle declines 
in parallel (Chapter 4) and so should its role in BCAA oxidation. 
When rats were fed a high protein diet chronically, muscle BCDH 
activity~ along with circulating BCAA concentrations, increased to a 
new "steady-statetl value during the postabsorptive period (Chapter 4). 
BCDH activity in liver and kidney however were decreased slightly by a 
high protein diet (137,151). Muscle therefore may be a central organ 
in the disposal of excesses of BCAA. The capacity of muscle to dispose 
of excess BCAA may be counterproductive when leucine alone is in 
excess. Under these conditions muscle BCDH activity increases (Chapter 
2) but since valine and isoleucine are also catabolized by BCDH they 
may be removed in excess and become limiting. Indeed, this may be the 
explanation for the observed depression of growth rate in animals fed 
diets' with excesses of leucine alone (77). 
In times of diminished supply, such as chronically feeding a low 
protein diet postabsorptive muscle BCDH activity was the same as in 
rats fed a normal diet (Chapter 4), it should be recalled though that 
this activity is very low (1-2% of total). BCDH activity in liver and 
kidney was markedly decreased by a low-protein diet (137,151). More 
remarkable though is the observation that the activation response of 
muscle BCDH to circulating BCAA from meal ingestion or leucine infusion 
is impaired (Chapter 4). This suggests that muscle adapts to times of 
diminished BCAA supply in a manner to slow or diminish muscle oxidation 
of BCAA when they are acquired. 
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The results of studies of BeAA catabolism in diabetes or during 
starvation (Chapter 2 and 5) suggest that the response of muscle BCDH 
to BCAA is blunted as it is in rats fed a low protein diet. Further-
more, BCDH activity in liver and kidney is also decreased in diabetes 
and during starvation (137,151). Despite the changes in muscle 
response to BCAA in diabetes and starvation, when BCAA concentrations 
are markedly elevated, muscle BCDH acti vi ty increases. Under these 
conditions diminished BCDH activity in liver and kidney may be more 
important to conservation of the BeAA, especially in view of the 
increased capacity of muscle to transaminate BCAA (Chapter 2). 
Although whole body BCAA oxidation increases in insulinopenic diabetes 
(154,179) and starvation (4), plasma BCAA concentrations also increase 
suggesting that their oxidation must nonetheless be restrained. It is 
unclear why the balance of oxidation and supply in diabetes and fasting 
is altered from the steady-state which obtains in normal rats, thus 
increasing plasma BCAA. It was postulated that increased BCAA may be 
beneficial in these conditions by maintaining basal insulin secretion 
which along wi th direct effects of BCAA could serve to maintain or 
augment protein synthesis (151). Furthermore, increased catabolism of 
BCAA in muscle may serve to restrain proteolysis (127) which is 
increased in these conditions (154,178). 
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